

525 Rec'd PCT/PTO 13 NOV 2000  
PATENT  
DOCKET NO. BM45321  
**09/700293**


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**BOX PCT/DO-EO**

Commissioner for Patents  
Washington, D.C. 20231

"Express Mail" mailing label number **EK 873 530 451 US**

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 CFR § 1.10 on the date indicated above and addressed to: Commissioner of Patents, Washington, DC 20231, on November 13, 2000.



Colleen Hanagan

**NATIONAL STAGE APPLICATION TRANSMITTAL LETTER  
APPLICATION FILING UNDER 35 U.S.C. § 371**

Transmitted herewith for filing is the patent application of:

Inventor(s)/Applicant(s): **Ruelle, Jean-Louis**  
International Application No.: **PCT/EP99/03255**  
International Published Appln. No.: **WO 99/58683**  
International Filing Date: **07 May 1999**  
Priority Filing Date: **13 May 1998**  
Thirty Month Date: **13 November 2000**  
Title: **"BASB029 POLYNUCLEOTIDE(S) AND  
POLYPEPTIDES FROM NEISSERIA  
MENINGITIDIS"**

**1. THIS NEW APPLICATION IS A NATIONAL STAGE  
APPLICATION UNDER PCT, CHAPTER II WITH A REQUEST FOR  
EXAMINATION WITHOUT DELAY TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US).**

- This is a **FIRST** submission of items concerning a filing under 35 U.S.C. § 371;
  - This is a **SECOND** or subsequent submission of items concerning a filing under 35 U.S.C. § 371.
2.  This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).

09/700293

529 Rec'd PCT/PTC PAPER  
DOCKET NO. BM45321

3. A proper Demand for International Preliminary Examination was made by the 19<sup>TH</sup> month from the earliest claimed priority date.

4. Enclosed items are required for filing under 37 CFR § 1.53(b) and § 1.494(b) or § 1.495(b):

- One copy of International Publication **WO 99/58683**
- (a)  is transmitted herewith (**required only if not transmitted by the International Bureau**)
- (b)  has been transmitted by the International Bureau
- (c)  is not required, as the application was filed in the United States Receiving Office (RO/US)

Fees

The basic national fee set forth in 37 CFR § 1.482 - International Preliminary Examination Fee not paid to USPTO but International Search Report prepared by the EPO or JPO - **\$860.00**

- Claims in Excess of 20 (14 @ \$18.00)
- Independent Claims in Excess of 3 (2 @ \$80.00)

5. Further enclosed are:

- One copy of International Preliminary Examination Report.
- One copy of International Search Report.
- One copy of Written Opinion.
- One copy of PCT Request as filed.
- One copy of Chapter II Demand as filed.

6.  A translation of the International Application into English (35 U.S.C. § 371(c)(2))

7.  Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. § 371(c)(3))

8.  A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. § 371(c)(3))

9. Still additional papers enclosed:

- Assignment with Assignment Recordation Form Cover Sheet
- Verification Statement Claiming Small Entity Status
- Declaration or oath is enclosed executed by the inventor
- An Information Disclosure Statement under 37 CFR § 1.97 and § 1.98
- Return Acknowledgment Postcard

Other:

PCT Request Form - Sheet Nos. 1-3

PCT/EPO Form 1030

10. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
- A. Enclosed are:
- (a)  Computer Readable Copy of the Sequence Listing
- (b)  Paper Copy (identical to Computer Readable Copy) of the Sequence Listing
- B.  Enclosed is a paper copy of the Sequence Listing. This paper copy and a Computer Readable Form thereof are identical with the Computer Readable Form in another application of the Applicant which is fully identified as follows:
- U.S. Application No.: @@
- Filed: @@
- Attorney Docket No.: @@
- which is believed to comply with the rules set forth in 37 CFR § 1.821 et. seq. Applicants requests pursuant to 37 CFR § 1.821(e) that this Computer Readable Form be used in the present application. **Please TRANSFER the sequence listing from the parent to this application.**
- C.  Statement under 37 CFR § 1.821(f): **The information recorded in computer readable form is identical to the written Sequence Listing.**
- D.  Statement under 37 CFR § 1.821(g) (required when Sequence Listing not submitted at the time of filing under 35 U.S.C. §111(a)) or 37 CFR §1.821(f) (required when Sequence Listing not submitted at the time of filing under the Patent Cooperation Treaty): **The submission of the Sequence Listing includes no new matter.**
- E.  Amendment: Please enter the Sequence Listing into the application.

11. **Preliminary Amendment**

Prior to calculation of fees, kindly enter:

- Preliminary Amendment submitted herewith
- do not enter Preliminary Amendment

09/700293  
529 Rec'd PCT/PTD 13 NOV 2000  
DOCKET NO. BM45321

12. Fee payment being made at this time is enclosed:

* Basic filing fee (\$860.00)	860.00
* Claims in Excess of 20	252.00
* (14 @ \$18.00)	
Independent Claims in Excess of 3	160.00
(2 @ \$80.00)	
* Total Fees enclosed:	<u>\$1272.00</u>

13. The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Account No. 50-0258. This letter is filed in duplicate for accounting purposes.

Respectfully submitted,



Arthur E. Jackson  
Registration No. 34,354  
Allen Bloom  
Registration No. 29,135  
Attorney for Applicant

DECHERT  
4000 Bell Atlantic Tower  
1717 Arch Street  
Philadelphia, PA 19103-2793  
Fax: (609) 620-3259  
Attn: Arthur E. Jackson, Esq.  
(609) 620-3254

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ruelle

Serial No.: Unknown

Filed: Herewith

Group Art Unit No.: Unknown

Examiner: Unknown

For: BASB029 Polynucleotide(s) and Polypeptides from *Neisseria Meningitidis*

**PRELIMINARY AMENDMENT**

Sir:

Please enter this Preliminary Amendment into the record of the above-identified patent application before the calculation of fees.

**In the Specification:**

Please insert the pages containing the sequence listings that are submitted herewith after the figures.

**In the Claims:**

Please delete the claims of the application as filed in the PCT and substitute therefor:

26. An isolated polypeptide comprising a member selected from the group consisting of
- (a) an amino acid sequence which has at least 90% identity to SEQ ID NOS:2 or 4;
  - (b) an immunogenic fragment of the amino acid sequence of (a), wherein the immunogenic fragment is at least 90% identical to an aligned contiguous segment of SEQ ID NOS:2 or 4; and
  - (c) an immunogenic fragment of the amino acid sequence of (a) that matches an aligned contiguous segment of SEQ ID NOS:2 or 4 with no more than five single amino acid substitutions, deletions or additions;

wherein the isolated polypeptide, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an immune response that recognizes a polypeptide having the sequence of SEQ ID NOS:2 or 4.

27. The isolated polypeptide of claim 26, wherein the immune response recognizes an antigen having molecular weight 65-70kD (by SDS PAGE) in *Neisseria meningitidis* strains H44/76, M97 250987, BZ10, BZ198, EG328, and ATCC 13090.

28. The isolated polypeptide of claim 26, wherein the immunogenic fragment of (b) comprises at least 15 amino acids.
29. The isolated polypeptide of claim 28, wherein the immunogenic fragment matches an aligned contiguous segment of SEQ ID NOs:2 or 4 with no more than a single amino acid substitution, deletion or addition.
30. The isolated polypeptide of claim 26, wherein the immunogenic fragment of (b) comprises at least 20 amino acids.
31. The isolated polypeptide of Claim 26 wherein the amino acid sequence of (a) has at least 95% identity to SEQ ID NOs:2 or 4.
32. The isolated polypeptide of Claim 31 wherein the isolated polypeptide comprises the amino acid sequence of SEQ ID NOs:2 or 4.
33. The isolated polypeptide of claim 31 wherein the isolated polypeptide consists of the amino acid sequence of SEQ ID NOs:2 or 4.
34. A fusion protein comprising the isolated polypeptide of Claim 26.
35. The isolated polypeptide of Claim 26 wherein the polypeptide is the immunogenic fragment having no more than two single amino acid substitutions, deletions or additions relative to the aligned sequence.
36. The isolated polypeptide of Claim 26 wherein the polypeptide is the immunogenic fragment having no more than one single amino acid substitution, deletion or addition relative to the aligned sequence.
37. The isolated polypeptide of Claim 26 wherein the polypeptide is the immunogenic fragment which matches the aligned sequence.

38. An isolated polypeptide encoded by an isolated first polynucleotide wherein the isolated first polynucleotide hybridizes under stringent conditions to a second polynucleotide which encodes the polypeptide of SEQ ID NOs:2 or 4; wherein stringent conditions comprise overnight incubation at 42° C in a solution comprising: 50% formamide, 5×SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5× Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1× SSC at about 65° C; wherein the isolated polypeptide, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an immune response that recognizes a polypeptide having the sequence of SEQ ID NOs:2 or 4.

39. An isolated polynucleotide encoding a polypeptide of Claim 26 or the full complement to the isolated polynucleotide.

40. An isolated polynucleotide encoding a polypeptide of Claim 26, wherein the isolated polynucleotide encodes the polypeptide comprising SEQ ID NOs:2 or 4.

41. An isolated polynucleotide comprising the polynucleotide of SEQ ID NOs:1 or 3.

42. An isolated polynucleotide segment comprising a polynucleotide sequence or the full complement of the entire length of the polynucleotide sequence, wherein the polynucleotide sequence hybridizes to the full complement of SEQ ID NOs:1 or 3 minus the full complement of any terminal stop codon, wherein the hybridization conditions include incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing in 0.1x SSC at 65°C; and, wherein the polynucleotide sequence is identical to SEQ ID NOs:1 or 3 minus any terminal stop codon, except that, over the entire length corresponding to SEQ ID NO:1 or 3 minus any terminal stop codon,  $n_n$  nucleotides are substituted, inserted or deleted, wherein  $n_n$  satisfies the following expression

$$n_n \leq x_n - (x_n \bullet y)$$

wherein  $x_n$  is the total number of nucleotides in SEQ ID NOs:1 or 3 minus any terminal stop codon,  $y$  is at least 0.95, and wherein any non-integer product of  $x_n$  and  $y$  is rounded down to

the nearest integer before subtracting the product from  $x_n$ ; and wherein the polynucleotide sequence detects *Neisseria meningitidis*.

43. An expression vector comprising the isolated polynucleotide of Claim 39.
44. A host cell transformed with the expression vector of Claim 43.
45. A process of producing an isolated polypeptide comprising (a) culturing the host cell of Claim 44 under conditions sufficient for the production of the encoded polypeptide and (b) recovering the polypeptide.
46. A nucleic acid vaccine comprising the isolated polynucleotide of Claim 39 and a pharmaceutically acceptable carrier.
47. An isolated polynucleotide segment comprising a polynucleotide sequence or the full complement of the entire length of the polynucleotide sequence, wherein the polynucleotide sequence is identical to SEQ ID NOs:1 or 3 minus any terminal stop codon, except that, over the entire length corresponding to SEQ ID NOs:1 or 3 minus any terminal stop codon,  $n_n$  nucleotides are substituted, inserted or deleted, wherein  $n_n$  satisfies the following expression
$$n_n \leq x_n - (x_n \bullet y)$$
wherein  $x_n$  is the total number of nucleotides in SEQ ID NOs:1 or 3 minus any terminal stop codon,  $y$  is at least 0.90, and wherein any non-integer product of  $x_n$  and  $y$  is rounded down to the nearest integer before subtracting the product from  $x_n$ ; and wherein the polynucleotide sequence detects *Neisseria meningitidis*.
48. The isolated polynucleotide of Claim 47 where  $y$  is at least 0.95.
49. An expression vector comprising the isolated polynucleotide of Claim 47 which codes for a polypeptide that, when administered to a mammal which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an immune response that recognizes a polypeptide having the sequence of SEQ ID NOs:2 or 4.

50. A host cell transformed with the isolated polynucleotide or an expression vector comprising the isolated polynucleotide of Claim 47.
51. A process of producing an isolated polypeptide comprising (a) culturing the host cell of Claim 50 under conditions sufficient for the production of the encoded polypeptide and (b) recovering the polypeptide.
52. A vaccine comprising the polypeptide of Claim 26 and a pharmaceutically acceptable carrier.
53. The vaccine of Claim 52, wherein the composition comprises at least one other *Neisseria meningitidis* antigen.
54. An antibody immunospecific for the polypeptide or immunogenic fragment of Claim 26.
55. A method for inducing an immune response in a mammal comprising administration of the polypeptide of Claim 26.
56. A method of diagnosing a *Neisseria meningitidis* infection, comprising identifying a polypeptide of Claim 26, or an antibody that is immunospecific for the polypeptide, present within a biological sample from an animal suspected of having such an infection.
57. A method for inducing an immune response in a mammal comprising administration of the isolated polynucleotide of Claim 39.
58. A therapeutic composition useful in treating humans with *Neisseria meningitidis* comprising at least one antibody directed against the polypeptide of claim 26 and a suitable pharmaceutical carrier.
59. A process for expressing the polynucleotide of Claim 39 comprising transforming a host cell with the expression vector comprising the polynucleotide and culturing the host cell under conditions sufficient for expression of the polynucleotide.

### REMARKS

Applicant respectfully requests that this Preliminary Amendment be entered in this case before the calculation of fees and before examination of the subject application.

### Claims

Claims 1-25 have been canceled without prejudice or disclaimer of the subject matter therein. Applicant reserves the right to prosecute, in one or more patent applications, the canceled claims, the claims to non-elected inventions, the claims as originally filed, and any other claims supported by the specification.

New claims 26-59 have been introduced. No new matter is added.

### Support

Support for the new claims is either obvious, or is as described in the text below. Particularly, support for the recitation of “five single amino acid substitutions, deletions or additions” may be found, for example, at page 6, lines 16-17. Support for compositions of the isolated polypeptide which include an adjuvant recited in the claims may be found, for example, at page 40, lines 14-15. Support for the stringent hybridization conditions may be found, for example, at page 14, lines 6-10. Support for the recitation of sequence relatedness such as “wherein the first polynucleotide sequence is identical to SEQ ID NOs:1 or 3 minus any terminal stop codon, except that, over the entire length corresponding to SEQ ID NOs:1 or 3 minus any terminal stop codon,  $n_n$  nucleotides are substituted, inserted or deleted, wherein  $n_n$  satisfies the following expression

$$n_n \leq x_n - (x_n \bullet y)$$

wherein  $x_n$  is the total number of nucleotides in SEQ ID NOs:1 or 3 minus any terminal stop codon,  $y$  is at least 0.90, and wherein any non-integer product of  $x_n$  and  $y$  is rounded down to the nearest integer before subtracting the product from  $x_n$ ” may be found in the specification, for example, at page 43, line 25 through page 44, line 20. Support for the recitation of “wherein the immune response recognizes an antigen having molecular weight 65-70kD (by SDS PAGE) in *Neisseria meningitidis* strains H44/76, M97 250987, BZ10, BZ198, EG328, and ATCC 13090” may be found, for example, in example 3 at page 52 and in Figures 4 and 5.

**Closing Remarks**

Entry of this Preliminary Amendment prior to calculation of fees and Examination and Allowance of the pending claims are respectfully requested.

Respectfully submitted,



Arthur E. Jackson  
Registration No. 34,354  
Allen Bloom  
Registration No. 29,135  
Attorneys for Applicant

DECHERT PRICE & RHOADS  
Princeton Pike Corporate Center  
PO Box 5218  
Princeton, New Jersey 08543-5218  
Allen Bloom (609) 620-3214  
Arthur E. Jackson (609) 620-3254  
Fax: (609) 620-3259  
Attn: Allen Bloom, Esq.  
(609) 620-3214

09 / 700293

BASB029 POLYNUCLEOTIDE(S) AND POLYPEPTIDES FROM *NEISSERIA MENINGITIDIS***FIELD OF THE INVENTION**

- 5 This invention relates to polynucleotides, (herein referred to as "BASB029 polynucleotide(s)"), polypeptides encoded by them (referred to herein as "BASB029" or "BASB029 polypeptide(s)"), recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including vaccines against bacterial infections. In a further aspect, the 10 invention relates to diagnostic assays for detecting infection of certain pathogens.

**BACKGROUND OF THE INVENTION**

- Neisseria meningitidis* (meningococcus) is a Gram-negative bacterium frequently isolated from the human upper respiratory tract. It occasionally causes invasive bacterial diseases 15 such as bacteremia and meningitis. The incidence of meningococcal disease shows geographical seasonal and annual differences (Schwartz, B., Moore, P.S., Broome, C.V.; Clin. Microbiol. Rev. 2 (Supplement), S18-S24, 1989). Most disease in temperate countries is due to strains of serogroup B and varies in incidence from 1-10/100,000/year total population sometimes reaching higher values (Kaczmarski, E.B. (1997), Commun. Dis. 20 Rep. Rev. 7: R55-9, 1995; Scholten, R.J.P.M., Bijlmer, H.A., Poolman, J.T. et al. Clin. Infect. Dis. 16: 237-246, 1993; Cruz, C., Pavez, G., Aguilar, E., et al. Epidemiol. Infect. 105: 119-126, 1990).

- Epidemics dominated by serogroup A meningococci, mostly in central Africa, are 25 encountered, sometimes reaching levels up to 1000/100,000/year (Schwartz, B., Moore, P.S., Broome, C.V. Clin. Microbiol. Rev. 2 (Supplement), S18-S24, 1989). Nearly all cases as a whole of meningococcal disease are caused by serogroup A, B, C, W-135 and Y meningococci and a tetravalent A, C, W-135, Y polysaccharide vaccine is available (Armand, J., Arminjon, F., Mynard, M.C., Lafaix, C., J. Biol. Stand. 10: 335-339, 1982).

The polysaccharide vaccines are currently being improved by way of chemical conjugating them to carrier proteins (Lieberman, J.M., Chiu, S.S., Wong, V.K., et al. JAMA 275 : 1499-1503, 1996).

5

A serogroup B vaccine is not available, since the B capsular polysaccharide was found to be nonimmunogenic, most likely because it shares structural similarity to host components (Wyle, F.A., Artenstein, M.S., Brandt, M.L. et al. J. Infect. Dis. 126: 514-522, 1972; Finne, J.M., Leinonen, M., Mäkelä, P.M. Lancet ii.: 355-357, 1983).

10

For many years efforts have been initiated and carried out to develop meningococcal outer membrane based vaccines (de Moraes, J.C., Perkins, B., Camargo, M.C. et al. Lancet 340: 1074-1078, 1992; Bjune, G., Hoiby, E.A. Gronnesby, J.K. et al. 338: 1093-1096, 1991). Such vaccines have demonstrated efficacies from 57% - 85% in older children (>4 years) and adolescents.

15

Many bacterial outer membrane components are present in these vaccines, such as PorA, PorB, Rmp, Opc, Opa, FrpB and the contribution of these components to the observed protection still needs futher definition. Other bacterial outer membrane components have

20

been defined by using animal or human antibodies to be potentially relevant to the induction of protective immunity, such as TbpB and NspA (Martin, D., Cadieux, N., Hamel, J., Brodeux, B.R., J. Exp. Med. 185: 1173-1183, 1997; Lissolo, L., Maître-Wilmotte, C., Dumas, p. et al., Inf. Immun. 63: 884-890, 1995). The mechanisms of protective immunity will involve antibody mediated bactericidal activity and opsonophagocytosis.

25

A bacteremia animal model has been used to combine all antibody mediated mechanisms (Saukkonen, K., Leinonen, M., Abdillahi, H. Poolman, J. T. Vaccine 7: 325-328, 1989). It is generally accepted that the late complement component mediated bactericidal mechanism is

crucial for immunity against meningococcal disease (Ross, S.C., Rosenthal P.J., Berberic. H.M., Densen, P. J. Infect. Dis. 155: 1266-1275, 1987).

The frequency of *Neisseria meningitidis* infections has risen dramatically in the past few  
5 decades. This has been attributed to the emergence of multiply antibiotic resistant strains  
and an increasing population of people with weakened immune systems. It is no longer  
uncommon to isolate *Neisseria meningitidis* strains that are resistant to some or all of the  
standard antibiotics. This phenomenon has created an unmet medical need and demand for  
new anti-microbial agents, vaccines, drug screening methods, and diagnostic tests for this  
10 organism.

### SUMMARY OF THE INVENTION

The present invention relates to BASB029, in particular BASB029 polypeptides and  
15 BASB029 polynucleotides, recombinant materials and methods for their production. In  
another aspect, the invention relates to methods for using such polypeptides and  
polynucleotides, including prevention and treatment of microbial diseases, amongst others.  
In a further aspect, the invention relates to diagnostic assays for detecting diseases  
associated with microbial infections and conditions associated with such infections, such  
20 as assays for detecting expression or activity of BASB029 polynucleotides or  
polypeptides.

Various changes and modifications within the spirit and scope of the disclosed invention  
will become readily apparent to those skilled in the art from reading the following  
25 descriptions and from reading the other parts of the present disclosure.

### DESCRIPTION OF THE INVENTION

The invention relates to BASB029 polypeptides and polynucleotides as described in greater detail below. In particular, the invention relates to polypeptides and polynucleotides of BASB029 of *Neisseria meningitidis*, which is related by amino acid sequence homology to *Haemophilus influenzae* surface fibril (HSF) protein. The invention relates especially to  
5 BASB029 having the nucleotide and amino acid sequences set out in SEQ ID NO:1,3 and SEQ ID NO:2,4 respectively. It is understood that sequences recited in the Sequence Listing below as "DNA" represent an exemplification of one embodiment of the invention, since those of ordinary skill will recognize that such sequences can be usefully employed in polynucleotides in general, including ribopolynucleotides.

10

### Polypeptides

In one aspect of the invention there are provided polypeptides of *Neisseria meningitidis* referred to herein as "BASB029" and "BASB029 polypeptides" as well as biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and  
15 compositions comprising the same.

The present invention further provides for:

- (a) an isolated polypeptide which comprises an amino acid sequence which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95%  
20 identity, most preferably at least 97-99% or exact identity, to that of SEQ ID NO:2, 4;
- (b) a polypeptide encoded by an isolated polynucleotide comprising a polynucleotide sequence which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% or exact identity to SEQ ID NO:1, 3 over the entire length of SEQ ID NO:1, 3 respectively; or
- 25 (c) a polypeptide encoded by an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% or exact identity, to the amino acid sequence of SEQ ID NO:2, 4;

The BASB029 polypeptides provided in SEQ ID NO:2.4 are the BASB029 polypeptides from *Neisseria meningitidis* strains ATCC13090 and H44/76.

The invention also provides an immunogenic fragment of a BASB029 polypeptide, that  
5 is, a contiguous portion of the BASB029 polypeptide which has the same or substantially  
the same immunogenic activity as the polypeptide comprising the amino acid sequence of  
SEQ ID NO:2.4. That is to say, the fragment (if necessary when coupled to a carrier) is  
capable of raising an immune response which recognises the BASB029 polypeptide.  
Such an immunogenic fragment may include, for example, the BASB029 polypeptide  
10 lacking an N-terminal leader sequence, and/or a transmembrane domain and/or a C-  
terminal anchor domain. In a preferred aspect the immunogenic fragment of BASB029  
according to the invention comprises substantially all of the extracellular domain of a  
polypeptide which has at least 85% identity, more preferably at least 90% identity, yet  
more preferably at least 95% identity, most preferably at least 97-99% identity, to that  
15 of SEQ ID NO:2.4 over the entire length of SEQ ID NO:2

A fragment is a polypeptide having an amino acid sequence that is entirely the same as part  
but not all of any amino acid sequence of any polypeptide of the invention. As with  
BASB029 polypeptides, fragments may be "free-standing," or comprised within a larger  
20 polypeptide of which they form a part or region, most preferably as a single continuous  
region in a single larger polypeptide.

Preferred fragments include, for example, truncation polypeptides having a portion of an  
amino acid sequence of SEQ ID NO:2.4 or of variants thereof, such as a continuous series of  
25 residues that includes an amino- and/or carboxyl-terminal amino acid sequence.  
Degradation forms of the polypeptides of the invention produced by or in a host cell, are  
also preferred. Further preferred are fragments characterized by structural or functional  
attributes such as fragments that comprise alpha-helix and alpha-helix forming regions,  
beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-

forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.

- 5 Further preferred fragments include an isolated polypeptide comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids from the amino acid sequence of SEQ ID NO:2,4, or an isolated polypeptide comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids truncated or deleted from the amino acid sequence of SEQ ID NO:2,4.

10

Fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these fragments may be employed as intermediates for producing the full-length polypeptides of the invention.

15

Particularly preferred are variants in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acids are substituted, deleted, or added in any combination.

- The polypeptides, or immunogenic fragments, of the invention may be in the form of  
20 the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production. Furthermore, addition of exogenous polypeptide or  
25 lipid tail or polynucleotide sequences to increase the immunogenic potential of the final molecule is also considered.

In one aspect, the invention relates to genetically engineered soluble fusion proteins comprising a polypeptide of the present invention, or a fragment thereof, and various

portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation 5 of a cleavage sequence which can be cleaved with blood clotting factor Xa.

Furthermore, this invention relates to processes for the preparation of these fusion proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and therapy. A further aspect of the invention also relates to polynucleotides encoding such 10 fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. WO94/29458 and WO94/22914.

The proteins may be chemically conjugated, or expressed as recombinant fusion proteins allowing increased levels to be produced in an expression system as compared 15 to non-fused protein. The fusion partner may assist in providing T helper epitopes (immunological fusion partner), preferably T helper epitopes recognised by humans, or assist in expressing the protein (expression enhancer) at higher yields than the native recombinant protein. Preferably the fusion partner will be both an immunological fusion partner and expression enhancing partner.

20

Fusion partners include protein D from *Haemophilus influenzae* and the non-structural protein from influenzae virus, NS1 (hemagglutinin). Another fusion partner is the protein known as LytA. Preferably the C terminal portion of the molecule is used. LytA is derived from *Streptococcus pneumoniae* which synthesize an N-acetyl-L- 25 alanine amidase, amidase LytA, (coded by the lytA gene {Gene, 43 (1986) page 265-272}) an autolysin that specifically degrades certain bonds in the peptidoglycan backbone. The C-terminal domain of the LytA protein is responsible for the affinity to the choline or to some choline analogues such as DEAE. This property has been exploited for the development of *E.coli* C-LytA expressing plasmids useful for

expression of fusion proteins. Purification of hybrid proteins containing the C-LytA fragment at its amino terminus has been described {Biotechnology: 10, (1992) page 795-798}. It is possible to use the repeat portion of the LytA molecule found in the C terminal end starting at residue 178, for example residues 188 - 305.

5

The present invention also includes variants of the aforementioned polypeptides, that is polypeptides that vary from the referents by conservative amino acid substitutions, whereby a residue is substituted by another with like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr.

10 Polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

15 It is most preferred that a polypeptide of the invention is derived from *Neisseria meningitidis*, however, it may preferably be obtained from other organisms of the same taxonomic genus. A polypeptide of the invention may also be obtained, for example, from organisms of the same taxonomic family or order.

### Polynucleotides

20 25 It is an object of the invention to provide polynucleotides that encode BASB029 polypeptides, particularly polynucleotides that encode the polypeptide herein designated BASB029.

In a particularly preferred embodiment of the invention the polynucleotide comprises a region encoding BASB029 polypeptides comprising a sequence set out in SEQ ID NO:1,3 which includes a full length gene, or a variant thereof.

- 5 The BASB029 polynucleotides provided in SEQ ID NO:1,3 are the BASB029 polynucleotides from *Neisseria meningitidis* strains ATCC13090 and H44/76.

As a further aspect of the invention there are provided isolated nucleic acid molecules encoding and/or expressing BASB029 polypeptides and polynucleotides, particularly

- 10 *Neisseria meningitidis* BASB029 polypeptides and polynucleotides, including, for example, unprocessed RNAs, ribozyme RNAs, mRNAs, cDNAs, genomic DNAs, B- and Z-DNAs. Further embodiments of the invention include biologically, diagnostically, prophylactically, clinically or therapeutically useful polynucleotides and polypeptides, and variants thereof, and compositions comprising the same.

- 15 Another aspect of the invention relates to isolated polynucleotides, including at least one full length gene, that encodes a BASB029 polypeptide having a deduced amino acid sequence of SEQ ID NO:2,4 and polynucleotides closely related thereto and variants thereof.

- 20 In another particularly preferred embodiment of the invention there is a BASB029 polypeptide from *Neisseria meningitidis* comprising or consisting of an amino acid sequence of SEQ ID NO:2,4 or a variant thereof.

- 25 Using the information provided herein, such as a polynucleotide sequence set out in SEQ ID NO:1, 3 a polynucleotide of the invention encoding BASB029 polypeptide may be obtained using standard cloning and screening methods, such as those for cloning and sequencing chromosomal DNA fragments from bacteria using *Neisseria meningitidis* cells as starting material, followed by obtaining a full length clone. For example, to obtain a polynucleotide sequence of the invention, such as a polynucleotide sequence given in SEQ ID NO:1,3,

typically a library of clones of chromosomal DNA of *Neisseria meningitidis* in *E.coli* or some other suitable host is probed with a radiolabeled oligonucleotide, preferably a 17-mer or longer, derived from a partial sequence. Clones carrying DNA identical to that of the probe can then be distinguished using stringent hybridization conditions. By 5 sequencing the individual clones thus identified by hybridization with sequencing primers designed from the original polypeptide or polynucleotide sequence it is then possible to extend the polynucleotide sequence in both directions to determine a full length gene sequence. Conveniently, such sequencing is performed, for example, using denatured double stranded DNA prepared from a plasmid clone. Suitable techniques are described 10 by Maniatis, T., Fritsch, E.F. and Sambrook et al., *MOLECULAR CLONING, A LABORATORY MANUAL*, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989). (see in particular Screening By Hybridization 1.90 and Sequencing Denatured Double-Stranded DNA Templates 13.70). Direct genomic DNA sequencing may also be performed to obtain a full length gene sequence. Illustrative of 15 the invention, each polynucleotide set out in SEQ ID NO:1.3 was discovered in a DNA library derived from *Neisseria meningitidis*.

Moreover, each DNA sequence set out in SEQ ID NO:1.3 contains an open reading frame encoding a protein having about the number of amino acid residues set forth in SEQ ID 20 NO:2, 4 with a deduced molecular weight that can be calculated using amino acid residue molecular weight values well known to those skilled in the art.

The polynucleotide of SEQ ID NO:1, between the start codon at nucleotide number 1 and the stop codon which begins at nucleotide number 1783 of SEQ ID NO:1, encodes the 25 polypeptide of SEQ ID NO:2.

The polynucleotide of SEQ ID NO:3, between the start codon at nucleotide number 1 and the stop codon which begins at nucleotide number 1774 of SEQ ID NO:3, encodes the polypeptide of SEQ ID NO:4.

In a further aspect, the present invention provides for an isolated polynucleotide comprising or consisting of:

- (a) a polynucleotide sequence which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% or exact identity to SEQ ID NO:1,3 over the entire length of SEQ ID NO:1,3 respectively; or
- (b) a polynucleotide sequence encoding a polypeptide which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% or 100% exact, to the amino acid sequence of SEQ ID NO:2, 4 over the entire length of SEQ ID NO:2, 4 respectively.

A polynucleotide encoding a polypeptide of the present invention, including homologs and orthologs from species other than *Neisseria meningitidis*, may be obtained by a process which comprises the steps of screening an appropriate library under stringent hybridization conditions (for example, using a temperature in the range of 45 – 65°C and an SDS concentration from 0.1 – 1%) with a labeled or detectable probe consisting of or comprising the sequence of SEQ ID NO: 1, 3 or a fragment thereof; and isolating a full-length gene and/or genomic clones containing said polynucleotide sequence.

- The invention provides a polynucleotide sequence identical over its entire length to a coding sequence (open reading frame) in SEQ ID NO: 1, 3. Also provided by the invention is a coding sequence for a mature polypeptide or a fragment thereof, by itself as well as a coding sequence for a mature polypeptide or a fragment in reading frame with another coding sequence, such as a sequence encoding a leader or secretory sequence, a pre-, or pro- or prepro-protein sequence. The polynucleotide of the invention may also contain at least one non-coding sequence, including for example, but not limited to at least one non-coding 5' and 3' sequence, such as the transcribed but non-translated sequences, termination signals (such as rho-dependent and rho-independent termination signals), ribosome binding sites, Kozak sequences, sequences that stabilize mRNA, introns, and polyadenylation signals.

The polynucleotide sequence may also comprise additional coding sequence encoding additional amino acids. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain embodiments of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, *Proc. Natl. Acad. Sci., USA* 86: 821-824 (1989), or an HA peptide tag (Wilson *et al.*, *Cell* 37: 767 (1984), both of which may be useful in purifying polypeptide sequence fused to them. Polynucleotides of the invention also include, but are not limited to, polynucleotides comprising a structural gene and its naturally associated sequences that control gene expression.

10

The nucleotide sequence encoding BASB029 polypeptide of SEQ ID NO:2, 4 may be identical to the polypeptide encoding sequence contained in nucleotides 1 to 1782 of SEQ ID NO:1, or the polypeptide encoding sequence contained in nucleotides 1 to 1773 of SEQ ID NO:3, respectively. Alternatively it may be a sequence, which as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2, 4.

The term "polynucleotide encoding a polypeptide" as used herein encompasses polynucleotides that include a sequence encoding a polypeptide of the invention, particularly a bacterial polypeptide and more particularly a polypeptide of the *Neisseria meningitidis* BASB029 having an amino acid sequence set out in SEQ ID NO:2, 4. The term also encompasses polynucleotides that include a single continuous region or discontinuous regions encoding the polypeptide (for example, polynucleotides interrupted by integrated phage, an integrated insertion sequence, an integrated vector sequence, an integrated transposon sequence, or due to RNA editing or genomic DNA reorganization) together with additional regions, that also may contain coding and/or non-coding sequences.

The invention further relates to variants of the polynucleotides described herein that encode variants of a polypeptide having a deduced amino acid sequence of SEQ ID NO:2, 4.

Fragments of polynucleotides of the invention may be used, for example, to synthesize full-length polynucleotides of the invention.

Further particularly preferred embodiments are polynucleotides encoding BASB029 variants, that have the amino acid sequence of BASB029 polypeptide of SEQ ID NO:2, 4 in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid residues are substituted, modified, deleted and/or added, in any combination. Especially preferred among these are silent substitutions, additions and deletions, that do not alter the properties and activities of BASB029 polypeptide.

10

Further preferred embodiments of the invention are polynucleotides that are at least 85% identical over their entire length to a polynucleotide encoding BASB029 polypeptide having an amino acid sequence set out in SEQ ID NO:2, 4, and polynucleotides that are complementary to such polynucleotides. In this regard, polynucleotides at least 90% identical over their entire length to the same are particularly preferred, and among these particularly preferred polynucleotides, those with at least 95% are especially preferred. Furthermore, those with at least 97% are highly preferred among those with at least 95%, and among these those with at least 98% and at least 99% are particularly highly preferred, with at least 99% being the more preferred.

15

Preferred embodiments are polynucleotides encoding polypeptides that retain substantially the same biological function or activity as the mature polypeptide encoded by a DNA of SEQ ID NO:1, 3.

20

In accordance with certain preferred embodiments of this invention there are provided polynucleotides that hybridize, particularly under stringent conditions, to BASB029 polynucleotide sequences, such as those polynucleotides in SEQ ID NO:1, 3.

The invention further relates to polynucleotides that hybridize to the polynucleotide sequences provided herein. In this regard, the invention especially relates to polynucleotides that hybridize under stringent conditions to the polynucleotides described herein. As herein used, the terms "stringent conditions" and "stringent hybridization conditions" mean

- 5 hybridization occurring only if there is at least 95% and preferably at least 97% identity between the sequences. A specific example of stringent hybridization conditions is overnight incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml of denatured, sheared salmon sperm
- 10 DNA, followed by washing the hybridization support in 0.1x SSC at about 65°C.

Hybridization and wash conditions are well known and exemplified in Sambrook, *et al.*, Molecular Cloning: A Laboratory Manual. Second Edition, Cold Spring Harbor, N.Y., (1989), particularly Chapter 11 therein. Solution hybridization may also be used with the polynucleotide sequences provided by the invention.

- 15 The invention also provides a polynucleotide consisting of or comprising a polynucleotide sequence obtained by screening an appropriate library containing the complete gene for a polynucleotide sequence set forth in SEQ ID NO:1, 3 under stringent hybridization conditions with a probe having the sequence of said polynucleotide sequence set forth in
- 20 SEQ ID NO:1, 3 or a fragment thereof; and isolating said polynucleotide sequence. Fragments useful for obtaining such a polynucleotide include, for example, probes and primers fully described elsewhere herein.

As discussed elsewhere herein regarding polynucleotide assays of the invention, for instance, the polynucleotides of the invention, may be used as a hybridization probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding BASB029 and to isolate cDNA and genomic clones of other genes that have a high identity, particularly high sequence identity, to the BASB029 gene. Such probes generally will comprise at least 15 nucleotide residues or base pairs. Preferably, such probes will have at

least 30 nucleotide residues or base pairs and may have at least 50 nucleotide residues or base pairs. Particularly preferred probes will have at least 20 nucleotide residues or base pairs and will have less than 30 nucleotide residues or base pairs.

- 5 A coding region of a BASB029 gene may be isolated by screening using a DNA sequence provided in SEQ ID NO:1, 3 to synthesize an oligonucleotide probe. A labeled oligonucleotide having a sequence complementary to that of a gene of the invention is then used to screen a library of cDNA, genomic DNA or mRNA to determine which members of the library the probe hybridizes to.

10

There are several methods available and well known to those skilled in the art to obtain full-length DNAs, or extend short DNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman, *et al.*, *PNAS USA* 85: 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon™

- 15 technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon™ technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the "missing" 5' end of the DNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using "nested" primers, that is, primers designed to anneal within the amplified product (typically an adaptor specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the selected gene sequence). The products of this reaction can then be analyzed by DNA sequencing and a full-length DNA constructed either by joining the product directly 20 to the existing DNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.
- 25

The polynucleotides and polypeptides of the invention may be employed, for example, as research reagents and materials for discovery of treatments of and diagnostics for diseases, particularly human diseases, as further discussed herein relating to polynucleotide assays.

- 5      The polynucleotides of the invention that are oligonucleotides derived from a sequence of SEQ ID NOS:1 – 4 may be used in the processes herein as described, but preferably for PCR, to determine whether or not the polynucleotides identified herein in whole or in part are transcribed in bacteria in infected tissue. It is recognized that such sequences will also have utility in diagnosis of the stage of infection and type of infection the pathogen has  
10     attained.

The invention also provides polynucleotides that encode a polypeptide that is the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, may allow protein transport, may lengthen or shorten protein half-life or may facilitate manipulation of a protein for assay or production, among other things. As generally is the case *in vivo*, the additional amino acids may be processed away from the mature protein by cellular enzymes.

- 20     For each and every polynucleotide of the invention there is provided a polynucleotide complementary to it. It is preferred that these complementary polynucleotides are fully complementary to each polynucleotide with which they are complementary.

- 25     A precursor protein, having a mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide. When prosequences are removed such inactive precursors generally are activated. Some or all of the prosequences may be removed before activation. Generally, such precursors are called proproteins.

In addition to the standard A, G, C, T/U representations for nucleotides, the term "N" may also be used in describing certain polynucleotides of the invention. "N" means that any of the four DNA or RNA nucleotides may appear at such a designated position in the DNA or RNA sequence, except it is preferred that N is not a nucleic acid that when taken in combination with adjacent nucleotide positions, when read in the correct reading frame, would have the effect of generating a premature termination codon in such reading frame.

In sum, a polynucleotide of the invention may encode a mature protein, a mature protein plus a leader sequence (which may be referred to as a preprotein), a precursor of a mature protein having one or more prosequences that are not the leader sequences of a preprotein, or a preproprotein, which is a precursor to a proprotein, having a leader sequence and one or more prosequences, which generally are removed during processing steps that produce active and mature forms of the polypeptide.

15 In accordance with an aspect of the invention, there is provided the use of a polynucleotide of the invention for therapeutic or prophylactic purposes, in particular genetic immunization.

The use of a polynucleotide of the invention in genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA into muscles (Wolff *et al.*, *Hum Mol Genet* (1992) 1: 363, Manthorpe *et al.*, *Hum. Gene Ther.* (1983) 4: 419), delivery of DNA complexed with specific protein carriers (Wu *et al.*, *J Biol Chem.* (1989) 264: 16985), coprecipitation of DNA with calcium phosphate (Benvenisty & Reshef, *PNAS USA*, (1986) 83: 9551), encapsulation of DNA in various forms of liposomes (Kaneda *et al.*, *Science* (1989) 243: 375), particle bombardment (Tang *et al.*, *Nature* (1992) 356:152, Eisenbraun *et al.*, *DNA Cell Biol* (1993) 12: 791) and *in vivo* infection using cloned retroviral vectors (Seeger *et al.*, *PNAS USA* (1984) 81: 5849).

**Vectors, Host Cells, Expression Systems**

The invention also relates to vectors that comprise a polynucleotide or polynucleotides of the invention, host cells that are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques. Cell-free

- 5 translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the invention.

Recombinant polypeptides of the present invention may be prepared by processes well known in those skilled in the art from genetically engineered host cells comprising

- 10 expression systems. Accordingly, in a further aspect, the present invention relates to expression systems that comprise a polynucleotide or polynucleotides of the present invention, to host cells which are genetically engineered with such expression systems, and to the production of polypeptides of the invention by recombinant techniques.

- 15 For recombinant production of the polypeptides of the invention, host cells can be genetically engineered to incorporate expression systems or portions thereof or polynucleotides of the invention. Introduction of a polynucleotide into the host cell can be effected by methods described in many standard laboratory manuals, such as Davis, *et al.*, *BASIC METHODS IN MOLECULAR BIOLOGY*, (1986) and Sambrook, *et al.*,

- 20 *MOLECULAR CLONING: A LABORATORY MANUAL*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989), such as, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction and infection.

- 25 Representative examples of appropriate hosts include bacterial cells, such as cells of streptococci, staphylococci, enterococci, *E. coli*, streptomycetes, cyanobacteria, *Bacillus subtilis*, *Moraxella catarrhalis*, *Haemophilus influenzae* and *Neisseria meningitidis*; fungal cells, such as cells of a yeast, *Kluveromyces*, *Saccharomyces*, a basidiomycete, *Candida*

*albicans* and *Aspergillus*; insect cells such as cells of *Drosophila* S2 and *Spodoptera* Sf9; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293, CV-1 and Bowes melanoma cells; and plant cells, such as cells of a gymnosperm or angiosperm.

- 5 A great variety of expression systems can be used to produce the polypeptides of the invention. Such vectors include, among others, chromosomal-, episomal- and virus-derived vectors, for example, vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses, picornaviruses, retroviruses, and alphaviruses and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression system constructs may contain control regions that regulate as well as engender expression. Generally, any system or vector suitable to maintain, propagate or express
- 10 15 polynucleotides and/or to express a polypeptide in a host may be used for expression in this regard. The appropriate DNA sequence may be inserted into the expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, *MOLECULAR CLONING, A LABORATORY MANUAL*. (*supra*).
- 20 In recombinant expression systems in eukaryotes, for secretion of a translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the expressed polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.
- 25 Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography,

hydroxylapatite chromatography and lectin chromatography. Most preferably, ion metal affinity chromatography (IMAC) is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis, isolation and or purification.

5

The expression system may also be a recombinant live microorganism, such as a virus or bacterium. The gene of interest can be inserted into the genome of a live recombinant virus or bacterium. Inoculation and *in vivo* infection with this live vector will lead to *in vivo* expression of the antigen and induction of immune responses. Viruses and bacteria used for this purpose are for instance: poxviruses (e.g; vaccinia, fowlpox, canarypox), alphaviruses (Sindbis virus, Semliki Forest Virus, Venezuelan Equine Encephalitis Virus), adenoviruses, adeno-associated virus, picornaviruses (poliovirus, rhinovirus), herpesviruses (varicella zoster virus, etc), Listeria, Salmonella, Shigella, Neisseria, BCG. These viruses and bacteria can be virulent, or attenuated in various ways in order to obtain live vaccines. Such live vaccines also form part of the invention.

10

15

#### Diagnostic, Prognostic, Serotyping and Mutation Assays

This invention is also related to the use of BASB029 polynucleotides and polypeptides of the invention for use as diagnostic reagents. Detection of BASB029 polynucleotides and/or polypeptides in a eukaryote, particularly a mammal, and especially a human, will provide a diagnostic method for diagnosis of disease, staging of disease or response of an infectious organism to drugs. Eukaryotes, particularly mammals, and especially humans, particularly those infected or suspected to be infected with an organism comprising the BASB029 gene or protein, may be detected at the nucleic acid or amino acid level by a variety of well known techniques as well as by methods provided herein.

20

25

Polypeptides and polynucleotides for prognosis, diagnosis or other analysis may be obtained from a putatively infected and/or infected individual's bodily materials. Polynucleotides from any of these sources, particularly DNA or RNA, may be used directly for detection or

may be amplified enzymatically by using PCR or any other amplification technique prior to analysis. RNA, particularly mRNA, cDNA and genomic DNA may also be used in the same ways. Using amplification, characterization of the species and strain of infectious or resident organism present in an individual, may be made by an analysis of the genotype of a selected polynucleotide of the organism. Deletions and insertions can be detected by a change in size of the amplified product in comparison to a genotype of a reference sequence selected from a related organism, preferably a different species of the same genus or a different strain of the same species. Point mutations can be identified by hybridizing amplified DNA to labeled BASB029 polynucleotide sequences. Perfectly or significantly matched sequences can be distinguished from imperfectly or more significantly mismatched duplexes by DNase or RNase digestion, for DNA or RNA respectively, or by detecting differences in melting temperatures or renaturation kinetics. Polynucleotide sequence differences may also be detected by alterations in the electrophoretic mobility of polynucleotide fragments in gels as compared to a reference sequence. This may be carried out with or without denaturing agents. Polynucleotide differences may also be detected by direct DNA or RNA sequencing. See, for example, Myers *et al.*, *Science*, 230: 1242 (1985). Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase, V1 and S1 protection assay or a chemical cleavage method. See, for example, Cotton *et al.*, *Proc. Natl. Acad. Sci., USA*, 85: 4397-4401 (1985).

In another embodiment, an array of oligonucleotides probes comprising BASB029 nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of, for example, genetic mutations, serotype, taxonomic classification or identification. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see, for example, Chee *et al.*, *Science*, 274: 610 (1996)).

Thus in another aspect, the present invention relates to a diagnostic kit which comprises:

- (a) a polynucleotide of the present invention, preferably the nucleotide sequence of SEQ ID NO:1, 3, or a fragment thereof ;  
(b) a nucleotide sequence complementary to that of (a);  
(c) a polypeptide of the present invention, preferably the polypeptide of SEQ ID NO:2, 4  
5 or a fragment thereof; or  
(d) an antibody to a polypeptide of the present invention, preferably to the polypeptide of SEQ ID NO:2, 4.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial  
10 component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease.  
among others.

This invention also relates to the use of polynucleotides of the present invention as  
diagnostic reagents. Detection of a mutated form of a polynucleotide of the invention,  
15 preferable, SEQ ID NO:1, 3, which is associated with a disease or pathogenicity will  
provide a diagnostic tool that can add to, or define, a diagnosis of a disease, a prognosis of a  
course of disease, a determination of a stage of disease, or a susceptibility to a disease,  
which results from under-expression, over-expression or altered expression of the  
polynucleotide. Organisms, particularly infectious organisms, carrying mutations in such  
20 polynucleotide may be detected at the polynucleotide level by a variety of techniques, such  
as those described elsewhere herein.

Cells from an organism carrying mutations or polymorphisms (allelic variations) in a  
polynucleotide and/or polypeptide of the invention may also be detected at the  
25 polynucleotide or polypeptide level by a variety of techniques, to allow for serotyping, for  
example. For example, RT-PCR can be used to detect mutations in the RNA. It is  
particularly preferred to use RT-PCR in conjunction with automated detection systems, such  
as, for example, GeneScan. RNA, cDNA or genomic DNA may also be used for the same

purpose, PCR. As an example, PCR primers complementary to a polynucleotide encoding BASB029 polypeptide can be used to identify and analyze mutations.

The invention further provides primers with 1, 2, 3 or 4 nucleotides removed from the 5' and/or the 3' end. These primers may be used for, among other things, amplifying 5  
BASB029 DNA and/or RNA isolated from a sample derived from an individual, such as a bodily material. The primers may be used to amplify a polynucleotide isolated from an infected individual, such that the polynucleotide may then be subject to various techniques for elucidation of the polynucleotide sequence. In this way, mutations in the polynucleotide 10 sequence may be detected and used to diagnose and/or prognose the infection or its stage or course, or to serotype and/or classify the infectious agent.

The invention further provides a process for diagnosing disease, preferably bacterial infections, more preferably infections caused by *Neisseria meningitidis*, comprising 15 determining from a sample derived from an individual, such as a bodily material, an increased level of expression of polynucleotide having a sequence of SEQ ID NO:1, 3. Increased or decreased expression of a BASB029 polynucleotide can be measured using any one of the methods well known in the art for the quantitation of polynucleotides, such as, for example, amplification, PCR, RT-PCR, RNase protection, Northern blotting, 20 spectrometry and other hybridization methods.

In addition, a diagnostic assay in accordance with the invention for detecting over-expression of BASB029 polypeptide compared to normal control tissue samples may be used to detect the presence of an infection, for example. Assay techniques that can be used 25 to determine levels of a BASB029 polypeptide, in a sample derived from a host, such as a bodily material, are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis, antibody sandwich assays, antibody detection and ELISA assays.

The polynucleotides of the invention may be used as components of polynucleotide arrays, preferably high density arrays or grids. These high density arrays are particularly useful for diagnostic and prognostic purposes. For example, a set of spots each comprising a different gene, and further comprising a polynucleotide or 5 polynucleotides of the invention, may be used for probing, such as using hybridization or nucleic acid amplification, using a probe obtained or derived from a bodily sample, to determine the presence of a particular polynucleotide sequence or related sequence in an individual. Such a presence may indicate the presence of a pathogen, particularly *Neisseria meningitidis*, and may be useful in diagnosing and/or prognosing disease or a 10 course of disease. A grid comprising a number of variants of the polynucleotide sequence of SEQ ID NO:1, 3 are preferred. Also preferred is a grid comprising a number of variants of a polynucleotide sequence encoding the polypeptide sequence of SEQ ID NO:2, 4.

15 **Antibodies**

The polypeptides and polynucleotides of the invention or variants thereof, or cells expressing the same can be used as immunogens to produce antibodies immunospecific for such polypeptides or polynucleotides respectively.

20 In certain preferred embodiments of the invention there are provided antibodies against BASB029 polypeptides or polynucleotides.

Antibodies generated against the polypeptides or polynucleotides of the invention can be obtained by administering the polypeptides and/or polynucleotides of the invention, or 25 epitope-bearing fragments of either or both, analogues of either or both, or cells expressing either or both, to an animal, preferably a nonhuman, using routine protocols. For preparation of monoclonal antibodies, any technique known in the art that provides antibodies produced by continuous cell line cultures can be used. Examples include various techniques, such as those in Kohler, G. and Milstein, C., *Nature* 256: 495-497 (1975);

Kozbor *et al.*, *Immunology Today* 4: 72 (1983); Cole *et al.*, pg. 77-96 in *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc. (1985).

Techniques for the production of single chain antibodies (U.S. Patent No. 4,946,778) can be  
5 adapted to produce single chain antibodies to polypeptides or polynucleotides of this invention. Also, transgenic mice, or other organisms or animals, such as other mammals, may be used to express humanized antibodies immunospecific to the polypeptides or polynucleotides of the invention.

10 Alternatively, phage display technology may be utilized to select antibody genes with binding activities towards a polypeptide of the invention either from repertoires of PCR amplified v-genes of lymphocytes from humans screened for possessing anti-BASB029 or from naive libraries (McCafferty, *et al.*, (1990), *Nature* 348, 552-554; Marks, *et al.*, (1992) *Biotechnology* 10, 779-783). The affinity of these antibodies can also be improved  
15 by, for example, chain shuffling (Clackson *et al.*, (1991) *Nature* 352: 628).

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptides or polynucleotides of the invention to purify the polypeptides or polynucleotides by, for example, affinity chromatography.

20 Thus, among others, antibodies against BASB029-polypeptide or BASB029-polynucleotide may be employed to treat infections, particularly bacterial infections.

25 Polypeptide variants include antigenically, epitopically or immunologically equivalent variants form a particular aspect of this invention.

Preferably, the antibody or variant thereof is modified to make it less immunogenic in the individual. For example, if the individual is human the antibody may most preferably be "humanized," where the complimentarity determining region or regions of the hybridoma-

derived antibody has been transplanted into a human monoclonal antibody, for example as described in Jones *et al.* (1986), *Nature* 321, 522-525 or Tempest *et al.*, (1991) *Biotechnology* 9, 266-273.

5

#### Antagonists and Agonists - Assays and Molecules

Polypeptides and polynucleotides of the invention may also be used to assess the binding of small molecule substrates and ligands in, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. These substrates and ligands may be natural substrates and ligands or may be structural or functional mimetics. See, e.g., Coligan *et al.*, 10 *Current Protocols in Immunology* 1(2): Chapter 5 (1991).

The screening methods may simply measure the binding of a candidate compound to the polypeptide or polynucleotide, or to cells or membranes bearing the polypeptide or 15 polynucleotide, or a fusion protein of the polypeptide by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve competition with a labeled competitor. Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide or polynucleotide, using detection systems appropriate to the 20 cells comprising the polypeptide or polynucleotide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Constitutively active polypeptide and/or constitutively expressed polypeptides and polynucleotides may be employed in screening methods for inverse agonists or inhibitors, in the absence of an agonist or 25 inhibitor, by testing whether the candidate compound results in inhibition of activation of the polypeptide or polynucleotide, as the case may be. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide or polynucleotide of the present invention, to form a mixture, measuring BASB029 polypeptide and/or polynucleotide activity in the mixture, and

comparing the BASB029 polypeptide and/or polynucleotide activity of the mixture to a standard. Fusion proteins, such as those made from Fc portion and BASB029 polypeptide, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists of the polypeptide of the present invention, as well as of phylogenetically and and/or functionally related polypeptides (see D. Bennett *et al.*, J Mol Recognition, 8:52-58 (1995); and K. Johanson *et al.*, J Biol Chem, 270(16):9459-9471 (1995)).

The polynucleotides, polypeptides and antibodies that bind to and/or interact with a polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and/or polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents which may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

The invention also provides a method of screening compounds to identify those which enhance (agonist) or block (antagonist) the action of BASB029 polypeptides or polynucleotides, particularly those compounds that are bacteriostatic and/or bactericidal. The method of screening may involve high-throughput techniques. For example, to screen for agonists or antagonists, a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, comprising BASB029 polypeptide and a labeled substrate or ligand of such polypeptide is incubated in the absence or the presence of a candidate molecule that may be a BASB029 agonist or antagonist. The ability of the candidate molecule to agonize or antagonize the BASB029 polypeptide is reflected in decreased binding of the labeled ligand or decreased production of product from such substrate. Molecules that bind gratuitously, *i.e.*, without inducing the effects of BASB029 polypeptide are most likely to be good antagonists. Molecules that bind well

and, as the case may be, increase the rate of product production from substrate, increase signal transduction, or increase chemical channel activity are agonists. Detection of the rate or level of, as the case may be, production of product from substrate, signal transduction, or chemical channel activity may be enhanced by using a reporter system. Reporter systems  
5 that may be useful in this regard include but are not limited to colorimetric, labeled substrate converted into product, a reporter gene that is responsive to changes in BASB029 polynucleotide or polypeptide activity, and binding assays known in the art.

Another example of an assay for BASB029 agonists is a competitive assay that combines  
10 BASB029 and a potential agonist with BASB029-binding molecules, recombinant BASB029 binding molecules, natural substrates or ligands, or substrate or ligand mimetics, under appropriate conditions for a competitive inhibition assay. BASB029 can be labeled, such as by radioactivity or a colorimetric compound, such that the number of BASB029 molecules bound to a binding molecule or converted to product can be determined  
15 accurately to assess the effectiveness of the potential antagonist.

Potential antagonists include, among others, small organic molecules, peptides, polypeptides and antibodies that bind to a polynucleotide and/or polypeptide of the invention and thereby inhibit or extinguish its activity or expression. Potential antagonists also may be small  
20 organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds the same sites on a binding molecule, such as a binding molecule, without inducing BASB029-induced activities, thereby preventing the action or expression of BASB029 polypeptides and/or polynucleotides by excluding BASB029 polypeptides and/or polynucleotides from binding.

25 Potential antagonists include a small molecule that binds to and occupies the binding site of the polypeptide thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented. Examples of small molecules include but are not limited to small organic molecules, peptides or peptide-like molecules. Other potential antagonists

include antisense molecules (see Okano, *J. Neurochem.* 56: 560 (1991); *OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION*, CRC Press, Boca Raton, FL (1988), for a description of these molecules). Preferred potential antagonists include compounds related to and variants of BASB029.

5

In a further aspect, the present invention relates to genetically engineered soluble fusion proteins comprising a polypeptide of the present invention, or a fragment thereof, and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa. Furthermore, this invention relates to processes for the preparation of these fusion proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and therapy. A further aspect of the invention also relates to polynucleotides encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. WO94/29458 and WO94/22914.

Each of the polynucleotide sequences provided herein may be used in the discovery and development of antibacterial compounds. The encoded protein, upon expression, can be used as a target for the screening of antibacterial drugs. Additionally, the polynucleotide sequences encoding the amino terminal regions of the encoded protein or Shine-Delgarno or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest.

25

The invention also provides the use of the polypeptide, polynucleotide, agonist or antagonist of the invention to interfere with the initial physical interaction between a pathogen or pathogens and a eukaryotic, preferably mammalian, host responsible for sequelae of infection. In particular, the molecules of the invention may be used: in the

prevention of adhesion of bacteria, in particular gram positive and/or gram negative bacteria, to eukaryotic, preferably mammalian, extracellular matrix proteins on in-dwelling devices or to extracellular matrix proteins in wounds; to block bacterial adhesion between eukaryotic, preferably mammalian, extracellular matrix proteins and bacterial

- 5 BASB029 proteins that mediate tissue damage and/or; to block the normal progression of pathogenesis in infections initiated other than by the implantation of in-dwelling devices or by other surgical techniques.

In accordance with yet another aspect of the invention, there are provided BASB029

- 10 agonists and antagonists, preferably bacteristatic or bactericidal agonists and antagonists.

The antagonists and agonists of the invention may be employed, for instance, to prevent, inhibit and/or treat diseases.

- 15 In a further aspect, the present invention relates to mimotopes of the polypeptide of the invention. A mimotope is a peptide sequence, sufficiently similar to the native peptide (sequentially or structurally), which is capable of being recognised by antibodies which recognise the native peptide: or is capable of raising antibodies which recognise the native peptide when coupled to a suitable carrier.

- 20 Peptide mimotopes may be designed for a particular purpose by addition, deletion or substitution of elected amino acids. Thus, the peptides may be modified for the purposes of ease of conjugation to a protein carrier. For example, it may be desirable for some chemical conjugation methods to include a terminal cysteine. In addition it may be  
25 desirable for peptides conjugated to a protein carrier to include a hydrophobic terminus distal from the conjugated terminus of the peptide, such that the free unconjugated end of the peptide remains associated with the surface of the carrier protein. Thereby presenting the peptide in a conformation which most closely resembles that of the peptide as found in the context of the whole native molecule. For example, the peptides

may be altered to have an N-terminal cysteine and a C-terminal hydrophobic amidated tail. Alternatively, the addition or substitution of a D-stereoisomer form of one or more of the amino acids may be performed to create a beneficial derivative, for example to enhance stability of the peptide.

5

Alternatively, peptide mimotopes may be identified using antibodies which are capable themselves of binding to the polypeptides of the present invention using techniques such as phage display technology (EP 0 552 267 B1). This technique, generates a large number of peptide sequences which mimic the structure of the native peptides and are, therefore, 10 capable of binding to anti-native peptide antibodies, but may not necessarily themselves share significant sequence homology to the native polypeptide.

### Vaccines

Another aspect of the invention relates to a method for inducing an immunological 15 response in an individual, particularly a mammal, preferably humans, which comprises inoculating the individual with BASB029 polynucleotide and/or polypeptide, or a fragment or variant thereof, adequate to produce antibody and/ or T cell immune response to protect said individual from infection, particularly bacterial infection and most particularly *Neisseria meningitidis* infection. Also provided are methods whereby such 20 immunological response slows bacterial replication. Yet another aspect of the invention relates to a method of inducing immunological response in an individual which comprises delivering to such individual a nucleic acid vector, sequence or ribozyme to direct expression of BASB029 polynucleotide and/or polypeptide, or a fragment or a variant thereof, for expressing BASB029 polynucleotide and/or polypeptide, or a fragment or a 25 variant thereof *in vivo* in order to induce an immunological response, such as, to produce antibody and/ or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said individual, preferably a human, from disease, whether that disease is already established within the individual or not. One example of administering the gene is by accelerating it into the desired cells as a coating on particles

or otherwise. Such nucleic acid vector may comprise DNA, RNA, a ribozyme, a modified nucleic acid, a DNA/RNA hybrid, a DNA-protein complex or an RNA-protein complex.

A further aspect of the invention relates to an immunological composition that when

- 5 introduced into an individual, preferably a human, capable of having induced within it an immunological response, induces an immunological response in such individual to a BASB029 polynucleotide and/or polypeptide encoded therefrom, wherein the composition comprises a recombinant BASB029 polynucleotide and/or polypeptide encoded therefrom and/or comprises DNA and/or RNA which encodes and expresses an antigen of said  
10 BASB029 polynucleotide, polypeptide encoded therefrom, or other polypeptide of the invention. The immunological response may be used therapeutically or prophylactically and may take the form of antibody immunity and/or cellular immunity, such as cellular immunity arising from CTL or CD4+ T cells.  
15 A BASB029 polypeptide or a fragment thereof may be fused with co-protein or chemical moiety which may or may not by itself produce antibodies, but which is capable of stabilizing the first protein and producing a fused or modified protein which will have antigenic and/or immunogenic properties, and preferably protective properties. Thus fused recombinant protein, preferably further comprises an antigenic co-protein, such as  
20 lipoprotein D from *Haemophilus influenzae*, Glutathione-S-transferase (GST) or beta-galactosidase, or any other relatively large co-protein which solubilizes the protein and facilitates production and purification thereof. Moreover, the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system of the organism receiving the protein. The co-protein may be attached to either the amino- or  
25 carboxy-terminus of the first protein.

Provided by this invention are compositions, particularly vaccine compositions, and methods comprising the polypeptides and/or polynucleotides of the invention and

immunostimulatory DNA sequences, such as those described in Sato, Y. *et al.* *Science* 273: 352 (1996).

Also, provided by this invention are methods using the described polynucleotide or  
5 particular fragments thereof, which have been shown to encode non-variable regions of bacterial cell surface proteins, in polynucleotide constructs used in such genetic immunization experiments in animal models of infection with *Neisseria meningitidis*.

Such experiments will be particularly useful for identifying protein epitopes able to provoke a prophylactic or therapeutic immune response. It is believed that this approach  
10 will allow for the subsequent preparation of monoclonal antibodies of particular value, derived from the requisite organ of the animal successfully resisting or clearing infection, for the development of prophylactic agents or therapeutic treatments of bacterial infection, particularly *Neisseria meningitidis* infection, in mammals, particularly humans.

15 The invention also includes a vaccine formulation which comprises an immunogenic recombinant polypeptide and/or polynucleotide of the invention together with a suitable carrier, such as a pharmaceutically acceptable carrier. Since the polypeptides and polynucleotides may be broken down in the stomach, each is preferably administered

20 parenterally, including, for example, administration that is subcutaneous, intramuscular, intravenous, or intradermal. Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostatic compounds and solutes which render the formulation isotonic with the bodily fluid, preferably the blood, of the individual; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The

25 formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use.

The vaccine formulation of the invention may also include adjuvant systems for enhancing the immunogenicity of the formulation. Preferably the adjuvant system raises preferentially a TH1 type of response.

- 5 An immune response may be broadly distinguished into two extreme categories, being a humoral or cell mediated immune responses (traditionally characterised by antibody and cellular effector mechanisms of protection respectively). These categories of response have been termed TH1-type responses (cell-mediated response), and TH2-type immune responses (humoral response).

10

Extreme TH1-type immune responses may be characterised by the generation of antigen specific, haplotype restricted cytotoxic T lymphocytes, and natural killer cell responses. In mice TH1-type responses are often characterised by the generation of antibodies of the IgG2a subtype, whilst in the human these correspond to IgG1 type antibodies. TH2-type immune responses are characterised by the generation of a broad range of immunoglobulin isotypes including in mice IgG1, IgA, and IgM.

15

It can be considered that the driving force behind the development of these two types of immune responses are cytokines. High levels of TH1-type cytokines tend to favour the induction of cell mediated immune responses to the given antigen, whilst high levels of TH2-type cytokines tend to favour the induction of humoral immune responses to the antigen.

20

The distinction of TH1 and TH2-type immune responses is not absolute. In reality an individual will support an immune response which is described as being predominantly TH1 or predominantly TH2. However, it is often convenient to consider the families of cytokines in terms of that described in murine CD4 +ve T cell clones by Mosmann and Coffman (*Mosmann, T.R. and Coffman, R.L. (1989) TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annual Review*

of Immunology, 7, p145-173). Traditionally, TH1-type responses are associated with the production of the INF- $\gamma$  and IL-2 cytokines by T-lymphocytes. Other cytokines often directly associated with the induction of TH1-type immune responses are not produced by T-cells, such as IL-12. In contrast, TH2-type responses are associated with the secretion of IL-4, IL-5, IL-6 and IL-13.

It is known that certain vaccine adjuvants are particularly suited to the stimulation of either TH1 or TH2-type cytokine responses. Traditionally the best indicators of the TH1:TH2 balance of the immune response after a vaccination or infection includes direct measurement of the production of TH1 or TH2 cytokines by T lymphocytes *in vitro* after restimulation with antigen, and/or the measurement of the IgG1:IgG2a ratio of antigen specific antibody responses.

Thus, a TH1-type adjuvant is one which preferentially stimulates isolated T-cell populations to produce high levels of TH1-type cytokines when re-stimulated with antigen *in vitro*, and promotes development of both CD8+ cytotoxic T lymphocytes and antigen specific immunoglobulin responses associated with TH1-type isotype.

Adjuvants which are capable of preferential stimulation of the TH1 cell response are described in International Patent Application No. WO 94/00153 and WO 95/17209.

3 De-O-acylated monophosphoryl lipid A (3D-MPL) is one such adjuvant. This is known from GB 2220211 (Ribi). Chemically it is a mixture of 3 De-O-acylated monophosphoryl lipid A with 4, 5 or 6 acylated chains and is manufactured by Ribi Immunochem, Montana. A preferred form of 3 De-O-acylated monophosphoryl lipid A is disclosed in European Patent 0 689 454 B1 (SmithKline Beecham Biologicals SA).

Preferably, the particles of 3D-MPL are small enough to be sterile filtered through a 0.22micron membrane (European Patent number 0 689 454).

3D-MPL will be present in the range of 10 $\mu$ g - 100 $\mu$ g preferably 25-50 $\mu$ g per dose wherein the antigen will typically be present in a range 2-50 $\mu$ g per dose.

Another preferred adjuvant comprises QS21, an Hplc purified non-toxic fraction derived  
5 from the bark of Quillaja Saponaria Molina. Optionally this may be admixed with 3  
De-O-acylated monophosphoryl lipid A (3D-MPL), optionally together with a carrier.

The method of production of QS21 is disclosed in US patent No. 5,057,540.

10 Non-reactogenic adjuvant formulations containing QS21 have been described previously (WO 96/33739). Such formulations comprising QS21 and cholesterol have been shown to be successful TH1 stimulating adjuvants when formulated together with an antigen.

15 Further adjuvants which are preferential stimulators of TH1 cell response include immunomodulatory oligonucleotides, for example unmethylated CpG sequences as disclosed in WO 96/02555.

Combinations of different TH1 stimulating adjuvants, such as those mentioned  
20 hereinabove, are also contemplated as providing an adjuvant which is a preferential stimulator of TH1 cell response. For example, QS21 can be formulated together with 3D-MPL. The ratio of QS21 : 3D-MPL will typically be in the order of 1 : 10 to 10 : 1; preferably 1:5 to 5 : 1 and often substantially 1 : 1. The preferred range for optimal synergy is 2.5 : 1 to 1 : 1 3D-MPL: QS21.

25 Preferably a carrier is also present in the vaccine composition according to the invention. The carrier may be an oil in water emulsion, or an aluminium salt, such as aluminium phosphate or aluminium hydroxide.

A preferred oil-in-water emulsion comprises a metabolisable oil, such as squalene, alpha tocopherol and Tween 80. In a particularly preferred aspect the antigens in the vaccine composition according to the invention are combined with QS21 and 3D-MPL in such an emulsion. Additionally the oil in water emulsion may contain span 85 and/or lecithin  
5 and/or tricaprylin.

Typically for human administration QS21 and 3D-MPL will be present in a vaccine in the range of 1 $\mu$ g - 200 $\mu$ g, such as 10-100 $\mu$ g, preferably 10 $\mu$ g - 50 $\mu$ g per dose.

Typically the oil in water will comprise from 2 to 10% squalene, from 2 to 10% alpha tocopherol and from 0.3 to 3% tween 80. Preferably the ratio of squalene: alpha tocopherol is equal to or less than 1 as this provides a more stable emulsion. Span 85 may also be present at a level of 1%. In some cases it may be advantageous that the vaccines of the present invention will further contain a stabiliser.  
10

15 Non-toxic oil in water emulsions preferably contain a non-toxic oil, e.g. squalane or squalene, an emulsifier, e.g. Tween 80, in an aqueous carrier. The aqueous carrier may be, for example, phosphate buffered saline.

20 A particularly potent adjuvant formulation involving QS21, 3D-MPL and tocopherol in an oil in water emulsion is described in WO 95/17210.

The present invention also provides a polyvalent vaccine composition comprising a vaccine formulation of the invention in combination with other antigens, in particular antigens useful for treating cancers, autoimmune diseases and related conditions. Such a  
25 polyvalent vaccine composition may include a TH-1 inducing adjuvant as hereinbefore described.

While the invention has been described with reference to certain BASB029 polypeptides and polynucleotides, it is to be understood that this covers fragments of the naturally

occurring polypeptides and polynucleotides, and similar polypeptides and polynucleotides with additions, deletions or substitutions which do not substantially affect the immunogenic properties of the recombinant polypeptides or polynucleotides.

- 5 The antigen can also be delivered in the form of whole bacteria (dead or alive) or as subcellular fractions, these possibilities do include *N.meningitidis* itself.

### **Compositions, kits and administration**

In a further aspect of the invention there are provided compositions comprising a BASB029 10 polynucleotide and/or a BASB029 polypeptide for administration to a cell or to a multicellular organism.

The invention also relates to compositions comprising a polynucleotide and/or a polypeptide discussed herein or their agonists or antagonists. The polypeptides and polynucleotides of 15 the invention may be employed in combination with a non-sterile or sterile carrier or carriers for use with cells, tissues or organisms, such as a pharmaceutical carrier suitable for administration to an individual. Such compositions comprise, for instance, a media additive or a therapeutically effective amount of a polypeptide and/or polynucleotide of the invention and a pharmaceutically acceptable carrier or excipient. Such carriers may include, but are 20 not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof. The formulation should suit the mode of administration. The invention further relates to diagnostic and pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

25

Polypeptides, polynucleotides and other compounds of the invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

The pharmaceutical compositions may be administered in any effective, convenient manner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal routes among others.

- 5 In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic.

In a further aspect, the present invention provides for pharmaceutical compositions  
10 comprising a therapeutically effective amount of a polypeptide and/or polynucleotide, such as the soluble form of a polypeptide and/or polynucleotide of the present invention, agonist or antagonist peptide or small molecule compound, in combination with a pharmaceutically acceptable carrier or excipient. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The invention further  
15 relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

Polypeptides, polynucleotides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

- 20 The composition will be adapted to the route of administration, for instance by a systemic or an oral route. Preferred forms of systemic administration include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if a polypeptide or other compounds of the present invention can be formulated in an enteric or an encapsulated formulation, oral  
25 administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels, solutions, powders and the like.

For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0.01 mg/kg to 10 mg/kg, typically around 1 mg/kg. The physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular  
5 individual. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

The dosage range required depends on the choice of peptide, the route of administration, the  
10 nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 µg/kg of subject.

A vaccine composition is conveniently in injectable form. Conventional adjuvants may be  
15 employed to enhance the immune response. A suitable unit dose for vaccination is 0.5-5 microgram/kg of antigen, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks. With the indicated dose range, no adverse toxicological effects will be observed with the compounds of the invention which would preclude their administration to suitable individuals.

20 Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted  
25 using standard empirical routines for optimization, as is well understood in the art.

#### Sequence Databases, Sequences in a Tangible Medium, and Algorithms

Polynucleotide and polypeptide sequences form a valuable information resource with which to determine their 2- and 3-dimensional structures as well as to identify further sequences of similar homology. These approaches are most easily facilitated by storing the sequence in a computer readable medium and then using the stored data in a known macromolecular  
5 structure program or to search a sequence database using well known searching tools, such as the GCG program package.

Also provided by the invention are methods for the analysis of character sequences or strings, particularly genetic sequences or encoded protein sequences. Preferred methods  
10 of sequence analysis include, for example, methods of sequence homology analysis, such as identity and similarity analysis. DNA, RNA and protein structure analysis, sequence assembly, cladistic analysis, sequence motif analysis, open reading frame determination, nucleic acid base calling, codon usage analysis, nucleic acid base trimming, and sequencing chromatogram peak analysis.  
15

15 A computer based method is provided for performing homology identification. This method comprises the steps of: providing a first polynucleotide sequence comprising the sequence of a polynucleotide of the invention in a computer readable medium; and comparing said first polynucleotide sequence to at least one second polynucleotide or  
20 polypeptide sequence to identify homology.

25 A computer based method is also provided for performing homology identification, said method comprising the steps of: providing a first polypeptide sequence comprising the sequence of a polypeptide of the invention in a computer readable medium; and comparing said first polypeptide sequence to at least one second polynucleotide or polypeptide sequence to identify homology.

All publications and references, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference in their

entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety in the manner described above for publications and references.

5

## DEFINITIONS

"Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as the case may be, as determined by comparing 10 the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" can be readily calculated by known methods, including but not limited to those described in (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; 15 *Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heine, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J.. eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., SIAM *J. 20 Applied Math.*, 48: 1073 (1988). Methods to determine identity are designed to give the largest match between the sequences tested. Moreover, methods to determine identity are codified in publicly available computer programs. Computer program methods to determine identity between two sequences include, but are not limited to, the GAP program in the GCG program package (Devereux, J.. et al., *Nucleic Acids Research* 12(1): 25 387 (1984)), BLASTP, BLASTN (Altschul, S.F. et al., *J. Molec. Biol.* 215: 403-410 (1990), and FASTA( Pearson and Lipman Proc. Natl. Acad. Sci. USA 85: 2444-2448 (1988). The BLAST family of programs is publicly available from NCBI and other sources (*BLAST Manual*, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894;

Altschul, S., et al., *J. Mol. Biol.* 215: 403-410 (1990). The well known Smith Waterman algorithm may also be used to determine identity.

Parameters for polypeptide sequence comparison include the following:

- 5      Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48: 443-453 (1970)  
Comparison matrix: BLOSUM62 from Henikoff and Henikoff,  
*Proc. Natl. Acad. Sci. USA.* 89:10915-10919 (1992)  
Gap Penalty: 8  
Gap Length Penalty: 2  
10     A program useful with these parameters is publicly available as the "gap" program from  
Genetics Computer Group, Madison WI. The aforementioned parameters are the default  
parameters for peptide comparisons (along with no penalty for end gaps).

Parameters for polynucleotide comparison include the following:

- 15     Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48: 443-453 (1970)  
Comparison matrix: matches = +10, mismatch = 0  
Gap Penalty: 50  
Gap Length Penalty: 3  
Available as: The "gap" program from Genetics Computer Group, Madison WI. These  
20     are the default parameters for nucleic acid comparisons.

A preferred meaning for "identity" for polynucleotides and polypeptides, as the case may be, are provided in (1) and (2) below.

- 25     (1) Polynucleotide embodiments further include an isolated polynucleotide comprising a polynucleotide sequence having at least a 50, 60, 70, 80, 85, 90, 95, 97 or 100% identity to the reference sequence of SEQ ID NO:1, wherein said polynucleotide sequence may be identical to the reference sequence of SEQ ID NO:1 or may include up to a certain integer number of nucleotide alterations as compared to the reference

sequence, wherein said alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either  
5 individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence, and wherein said number of nucleotide alterations is determined by multiplying the total number of nucleotides in SEQ ID NO:1 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of nucleotides in SEQ ID NO:1, or:

10

$$n_n \leq x_n - (x_n \bullet y),$$

wherein  $n_n$  is the number of nucleotide alterations,  $x_n$  is the total number of nucleotides in SEQ ID NO:1,  $y$  is 0.50 for 50%, 0.60 for 60%, 0.70 for 70%, 0.80 for 80%, 0.85 for  
15 85%, 0.90 for 90%, 0.95 for 95%, 0.97 for 97% or 1.00 for 100%, and • is the symbol for the multiplication operator, and wherein any non-integer product of  $x_n$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_n$ . Alterations of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by  
20 the polynucleotide following such alterations.

By way of example, a polynucleotide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:1, that is it may be 100% identical, or it may include up to a certain integer number of nucleic acid alterations as compared to the  
25 reference sequence such that the percent identity is less than 100% identity. Such alterations are selected from the group consisting of at least one nucleic acid deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference polynucleotide sequence or anywhere between those terminal positions, interspersed either individually

among the nucleic acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of nucleic acid alterations for a given percent identity is determined by multiplying the total number of nucleic acids in SEQ ID NO:1 by the integer defining the percent identity divided by 100 and then subtracting that

5 product from said total number of nucleic acids in SEQ ID NO:1, or:

$$n_n \leq x_n - (x_n \bullet y),$$

wherein  $n_n$  is the number of nucleic acid alterations,  $x_n$  is the total number of nucleic

10 acids in SEQ ID NO:1,  $y$  is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc.. •  
is the symbol for the multiplication operator, and wherein any non-integer product of  $x_n$   
and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_n$ .

(2) Polypeptide embodiments further include an isolated polypeptide comprising a  
15 polypeptide having at least a 50, 60, 70, 80, 85, 90, 95, 97 or 100% identity to a  
polypeptide reference sequence of SEQ ID NO:2, wherein said polypeptide sequence may  
be identical to the reference sequence of SEQ ID NO:2 or may include up to a certain  
integer number of amino acid alterations as compared to the reference sequence, wherein  
said alterations are selected from the group consisting of at least one amino acid deletion,  
20 substitution, including conservative and non-conservative substitution, or insertion, and  
wherein said alterations may occur at the amino- or carboxy-terminal positions of the  
reference polypeptide sequence or anywhere between those terminal positions,  
interspersed either individually among the amino acids in the reference sequence or in one  
or more contiguous groups within the reference sequence, and wherein said number of  
25 amino acid alterations is determined by multiplying the total number of amino acids in  
SEQ ID NO:2 by the integer defining the percent identity divided by 100 and then  
subtracting that product from said total number of amino acids in SEQ ID NO:2, or:

$$n_a \leq x_a - (x_a \bullet y),$$

wherein  $n_a$  is the number of amino acid alterations,  $x_a$  is the total number of amino acids in SEQ ID NO:2,  $y$  is 0.50 for 50%, 0.60 for 60%, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, 0.97 for 97% or 1.00 for 100%, and • is the symbol for the multiplication operator, and wherein any non-integer product of  $x_a$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_a$ .

By way of example, a polypeptide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:2, that is it may be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the percent identity is less than 100% identity. Such alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in SEQ ID NO:2 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of amino acids in SEQ ID NO:2, or:

$$n_a \leq x_a - (x_a \bullet y),$$

wherein  $n_a$  is the number of amino acid alterations,  $x_a$  is the total number of amino acids in SEQ ID NO:2,  $y$  is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and • is the symbol for the multiplication operator, and wherein any non-integer product of  $x_a$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_a$ .

"Individual(s)," when used herein with reference to an organism, means a multicellular eukaryote, including, but not limited to a metazoan, a mammal, an ovid, a bovid, a simian, a primate, and a human.

5 "Isolated" means altered "by the hand of man" from its natural state, *i.e.*, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Moreover, a polynucleotide or 10 polypeptide that is introduced into an organism by transformation, genetic manipulation or by any other recombinant method is "isolated" even if it is still present in said organism, which organism may be living or non-living.

15 "Polynucleotide(s)" generally refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA including single and double-stranded regions.

20 "Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical 25 variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino

acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques  
5 or by direct synthesis.

"Disease(s)" means any disease caused by or related to infection by a bacteria, including , for example, upper respiratory tract infection, invasive bacterial diseases. such as bacteremia and meningitis.

**EXAMPLES:**

The examples below are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. The examples  
5 are illustrative, but do not limit the invention.

**Example1: Discovery and confirmatory DNA sequencing of the BASB029 gene from two *N.meningitidis* strains.**

10 **A: BASB029 in *N. meningitidis* serogroup B strain ATCC13090.**

The BASB029 gene of SEQ ID NO:1 was first discovered in the Incyte PathoSeq database containing unfinished genomic DNA sequences of the *N. meningitidis* strain ATCC13090. The translation of the BASB029 polynucleotide sequence, showed in SEQ ID NO:2, showed significant similarity (52 % identity in a 582 amino acids overlap) to the *Haemophilus influenzae* surface fibril (HSF) protein.

15 The sequence of the BASB029 gene was further confirmed experimentally. For this purpose, genomic DNA was extracted from  $10^{10}$  cells of the *N.meningitidis* cells (strain ATCC 13090) using the QIAGEN genomic DNA extraction kit (Qiagen GmbH), and 1 $\mu$ g of this material was submitted to Polymerase Chain Reaction DNA amplification  
20 using primers Hsf1 (5'- GGG GCA TAT GAA CAA AAT ATA CCG CAT CAT TTG GAA-3') [SEQ ID NO:5] containing an internal *Nde*I site (underlined) and Hsf2 (5'- GGG GCT CGA GCC ACT GAT AAC CGA CAG ATG CGG A-3') [SEQ ID NO:6] containing an internal *Xho*I site (underlined). This PCR product was gel-purified and subjected to DNA sequencing using the Big Dye Cycle Sequencing kit (Perkin-Elmer)  
25 and an ABI 373A/PRISM DNA sequencer. DNA sequencing was performed on both strands with a redundancy of 2 and the full-length sequence was assembled using the SeqMan program from the DNASTAR Lasergene software package. The resulting DNA sequence turned out to be 100 % identical to SEQ ID NO:1.

**B: BASB029 in *N. meningitidis* serogroup B strain H44/76.**

The sequence of the BASB029 gene was also determined in another *N. meningitidis* serogroup B strain, the strain H44/76. For this purpose, genomic DNA was extracted from the *N. meningitidis* strain H44/76 using the experimental conditions presented in

- 5 Example 1. This material (1 µg) was then submitted to Polymerase Chain Reaction DNA amplification using primers Hsf1 and Hsf2 specific for the BASB029 gene. A 4389bp DNA fragment was obtained, digested by the *Nde*I/*Xho*I restriction endonucleases and inserted into the corresponding sites of the pET-24b cloning/expression vector (Novagen) using standard molecular biology techniques (Molecular Cloning,a  
10 Laboratory Manual, Second Edition, Eds: Sambrook, Fritsch & Maniatis, Cold Spring Harbor press 1989). Recombinant pET-24b/BASB029 was then submitted to DNA sequencing using the Big Dyes kit (Applied biosystems) and analyzed on a ABI 373/A DNA sequencer in the conditions described by the supplier. As a result, the polynucleotide and deduced polypeptide sequences, referred to as SEQ ID NO:3 and  
15 SEQ ID NO:4 respectively, were obtained. Using the PILEUP program from the GCG package, an alignment of the polynucleotide sequences of SEQ ID NO:1 and 3 was performed, and is displayed in Figure 1; their level of identity amounts to 96.8 % as determined by the GAP program. Using the same PILEUP program, an alignment of the polypeptide sequences of SEQ ID NO:2 and 4 was performed, and is displayed in  
20 Figure 2: their level of identity amounts to 94.2 %, as determined by the GAP program. Taken together, these data indicate strong sequence conservation of the BASB029 gene among the two *N.meningitidis* serogroup B strains.

25

**Example 2: Expression and purification of recombinant BASB029 protein in *Escherichia coli*.**

The construction of the pET-24b/BASB029 cloning/expression vector was described in Example 1B. This vector harbours the BASB029 gene isolated from the strain H44/76 in fusion with a stretch of 6 Histidine residues, placed under the control of the strong bacteriophage T7 gene 10 promoter. For expression study, this vector was introduced into 5 the *Escherichia coli* strain Novablue (DE3) (Novagen), in which, the gene for the T7 polymerase is placed under the control of the isopropyl-beta-D thiogalactoside (IPTG)- regulatable *lac* promoter. Liquid cultures (100 ml) of the Novablue (DE3) [pET- 24b/BASB029] *E. coli* recombinant strain were grown at 37°C under agitation until the optical density at 600nm (OD600) reached 0.6. At that time-point, IPTG was added at a 10 final concentration of 1mM and the culture was grown for 4 additional hours. The culture was then centrifuged at 10,000 rpm and the pellet was frozen at -20°C for at least 10 hours. After thawing, the pellet was resuspended during 30 min at 25°C in buffer A (6M guanidine hydrochloride, 0.1M NaH<sub>2</sub>PO<sub>4</sub>, 0.01M Tris, pH 8.0), passed three-times through a needle and clarified by centrifugation (20000rpm, 15 min). The sample was 15 then loaded at a flow-rate of 1ml/min on a Ni<sup>2+</sup> -loaded Hitrap column (Pharmacia Biotech). After passsage of the flowthrough, the column was washed succesively with 40ml of buffer B (8M Urea, 0.1MNaH<sub>2</sub>PO<sub>4</sub>, 0.01M Tris, pH 8.0), 40ml of buffer C (8M Urea, 0.1MNaH<sub>2</sub>PO<sub>4</sub>, 0.01M Tris, pH 6.3). The recombinant protein BASB029/His6 was then eluted from the column with 30ml of buffer D (8M Urea, 0.1MNaH<sub>2</sub>PO<sub>4</sub>, 0.01M 20 Tris, pH 6.3) containing 500mM of imidazole and 3ml-size fractions were collected. As shown in Figure 3 (lane1), a highly enriched (Purity estimated to more than 90% pure in coomassie staining) BASB029/His6 protein, migrating at 66kDa (estimated relative molecular mass), was eluted from the column. This polypeptide was reactive against a mouse monoclonal antibody raised against the 5-histidine motif (see figure 3, lane2). 25 Taken together, these data indicate that the BASB029 gene can be expressed and purified under a recombinant form (BASB029/His6) in *E.coli*.

**Example 3 : Immunization of mice with recombinant BASB029**

Partially purified recombinant BASB029 protein expressed in E. coli has been injected

5 three times in Balb/C mice on days 0, 14 and 29 (8 animals/group). Animals were  
injected by the subcutaneous route with around 5µg of antigen in two different  
formulations : either adsorbed on 100µg AlPO<sub>4</sub> or formulated in SBAS2 emulsion  
(SB62 emulsion containing 5µg MPL and 5µg QS21 per dose). A negative control  
group consisting of mice immunized with the SBAS2 emulsion only has also been  
10 added in the experiment. Mice were bled on days 29 (15 days Post II) and 35 (6 days  
Post III) in order to detect specific anti-BASB029 antibodies. Specific anti-BASB029  
antibodies were measured on pooled sera (from 10 mice/group) by western-blotting on  
six different NmB strains (Figures 4 and 5).

15 *Recognition of the BASB029 epitopes on different NmB strains by western-blotting*

In this test, immunized mice sera (pooled) have been tested by western-blotting for  
recognition of the BASB029 epitopes on six different neisseria meningitidis B strains :  
H44/76 (B:15:P1.7, 16, lineage ET-5), M97 250987 (B:4:P1.15), BZ10 (B:2b:P1.2,  
lineage A4), BZ198 (B:NT\*: -, lineage 3), EG328 (B:NT\*, lineage ST-18), and the  
20 ATCC 13090 Men B strain, as well as on partially purified recombinant BASB029  
protein (\* : NT : Not Typed).

Briefly, 10µl (> 10<sup>8</sup> cells/lane) of each sample treated with sample buffer (10 min at  
95°C) are put into a SDS-PAGE gradient gel (Tris-glycine 4-20%, Novex, code  
n°EC60252). Electrophoretic migration occurs at 125 volts for 90 min. Afterwards,  
25 proteins are transferred to nitrocellulose sheet (0.45µm, Bio-rad code n° 162-0114) at  
100 volts for 1 hour using a Bio-rad Trans-blot system (code n°170-3930). Filter was  
blocked with PBS - 0.05% Tween 20 overnight at room temperature, before incubation  
with the mice sera containing the anti-BASB029 antibodies coming from both AlPO<sub>4</sub>  
and SBAS2 formulations. These sera are diluted 100 times in PBS - 0.05% Tween 20,  
30 and incubated on the nitrocellulose sheet for two hours at room temperature with gentle

shaking, using a mini-blotter system (Miniprotean, Bio-rad code n° 170-4017). After three repeated washing steps in PBS - 0.05% Tween 20 for 5 min., the nitrocellulose sheet is incubated at room temperature for 1hour under gentle shaking with the appropriate conjugate (biotinylated anti-mouse Ig antibodies from sheep, Amersham code n°RPN1001) diluted at 1/500 in the same washing buffer. The membrane is washed three times as previously, and incubated for 30 min with agitation using the streptavidin-peroxidase complex (Amersham code n°1051) diluted at 1/1000 in the washing buffer. After the last three repeated washing steps, the revelation occurs during the 20 min incubation time in a 50 ml solution containing 30 mg 4-chloro-1-naphtol (Sigma), 10ml methanol, 40 ml PBS, and 30µl of H<sub>2</sub>O<sub>2</sub>. The staining is stopped while washing the membrane several times in distilled water.

Results illustrated in Figures 4 and 5 show that all strains tested present the expected band around 65-70 kDa, and two other major bands around 55 and 90 kD, which are clearly related to this BASB029 protein (polymers, degradation products). This means that the BASB029 protein is probably expressed in most of, if not all, the NmB strains. In Figure 4, the recombinant BASB029 protein appears as four different proteins, two at the expected molecular weights of 65-70 Kda, and two others at very molecular heights (> 200 kDa) which are probably aggregates of recombinant BASB029 protein.

20

25 **Example 4: Presence of anti-BASB029 antibodies in sera from convalescent patients.**

In this test, convalescent sera have been tested by western-blotting for recognition of the purified recombinant BASB029 protein.

Briefly, 5 $\mu$ g of partially purified BASB029 NmB protein are put into a SDS-PAGE gradient gel (4-20%, Novex, code n°EC60252) for electrophoretic migration. Proteins are transferred to nitrocellulose sheet (0.45 $\mu$ m, Bio-rad code n° 162-0114) at 100 volts for 1 hour using a Bio-rad Trans-blot system (code n°170-3930). Afterwards, filter is  
5 blocked with PBS - 0.05 % Tween 20 overnight at room temperature, before incubation with the human sera. These sera are diluted 100 times in PBS - 0.05% Tween 20, and incubated on the nitrocellulose sheet for two hours at room temperature with gentle shaking, using a mini-blotter system (Miniprotean, Bio-rad code n° 170-4017). After three repeated washing steps in PBS - 0.05% Tween 20 for 5 min., the nitrocellulose  
10 sheet is incubated at room temperature for 1hour under gentle shaking with the appropriate conjugate (biotinylated anti-human Ig antibodies, from sheep, Amersham code n°RPN1003) diluted at 1/500 in the same washing buffer. The membrane is washed three times as previously, and incubated for 30 min with agitation using the streptavidin-peroxidase complex (Amersham code n°1051) diluted at 1/1000 in the  
15 washing buffer. After the last three repeated washing steps, the revelation occurs during the 20 min incubation time in a 50ml solution containing 30 mg 4-chloro-1-naphtol (Sigma), 10ml methanol, 40ml of ultra-pure water, and 30 $\mu$ l of H<sub>2</sub>O<sub>2</sub>. The staining is stopped while washing the membrane several times in distilled water.

Results are illustrated in Figures 6 and 7 which show that all 7 convalescents react against  
20 the rec. BASB029 protein at around 65 – 70 kDa, while the two upper bands (> 200 kDa) are also recognized by most of them, while with a weak reaction for few of them. Reactivities against the high MW proteins confirms that these two bands are clearly related to the BASB029 protein, which are probably under their aggregated forms. In part A of the Figures 6 and 7, the same reactions against these four bands are seen with the  
25 immunized mice sera. This clearly confirms that all these four bands are related to the recombinant BASB029 protein. Negative mice sera don't react with the recombinant protein as shown also in Fig 7.

**Deposited materials**

A deposit containing a *Neisseria meningitidis* Serogroup B strain has been deposited with the American Type Culture Collection (herein "ATCC") on June 22, 1997 and assigned 5 deposit number 13090. The deposit was described as *Neisseria meningitidis* (Albrecht and Ghon) and is a freeze-dried, 1.5-2.9 kb insert library constructed from *N. meningitidis* isolate. The deposit is described in Int. Bull. Bacteriol. Nomencl. Taxon. 8: 1-15 (1958).

The *Neisseria meningitidis* strain deposit is referred to herein as "the deposited strain" or as 10 "the DNA of the deposited strain."

The deposited strain contains the full length BASB029 gene. The sequence of the polynucleotides contained in the deposited strain, as well as the amino acid sequence of any polypeptide encoded thereby, are controlling in the event of any conflict with any 15 description of sequences herein.

The deposit of the deposited strain has been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure. The strain will be irrevocably and without restriction or condition released to the 20 public upon the issuance of a patent. The deposited strain is provided merely as convenience to those of skill in the art and is not an admission that a deposit is required for enablement, such as that required under 35 U.S.C. §112.

**INDICATIONS RELATING TO DEPOSITED MICROORGANISM  
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on page <u>55</u> , line <u>1-22</u>	
<b>B. IDENTIFICATION OF DEPOSIT</b>	
Name of depositary institution  <b>AMERICAN TYPE CULTURE COLLECTION</b>	
Address of depositary institution ( <i>including postal code and country</i> )  <b>10801 UNIVERSITY BLVD, MANASSAS, VIRGINIA 20110-2209, UNITED STATES OF AMERICA</b>	
Date of deposit  <b>22 June 1997 (22/06/97)</b>	Accession Number  <b>13090</b>
<b>C. ADDITIONAL INDICATIONS</b> ( <i>leave blank if not applicable</i> )	
This information is continued on an additional sheet <input type="checkbox"/>	
In respect of those designations where a European Patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European Patent or until the date on which the application has been refused or withdrawn, only by issue of such a sample to an expert nominated by the person requesting the sample.	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> ( <i>if the indications are not for all designated States</i> )	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> ( <i>leave blank if not applicable</i> )	
The indications listed below will be submitted to the International Bureau later ( <i>specify the general nature of the indications e.g., "Accession Number of Deposit"</i> )	
For receiving Office use only	
<input type="checkbox"/> This sheet was received with the international application	
Authorized officer	
For International Bureau use only	
<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer	

**ART 34 AMDT****CLAIMS:**

1. An isolated polypeptide comprising an amino acid sequence which has at least 85% identity to the amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:4 over the entire length of SEQ ID NO:2 or SEQ ID NO:4 respectively.
2. An isolated polypeptide as claimed in claim 1 in which the amino acid sequence has at least 95% identity to the amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:4 over the entire length of SEQ ID NO:2 or SEQ ID NO:4 respectively.
3. The polypeptide as claimed in claim 1 comprising the amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:4.
4. An isolated polypeptide of SEQ ID NO:2, SEQ ID NO:4.
5. A polypeptide comprising an immunogenic fragment of the polypeptide as claimed in any one of claims 1 to 4 in which the immunogenic fragment is capable of raising an immune response which recognises the polypeptide of SEQ ID NO:2, SEQ ID NO:4.
6. A polypeptide according to claim 5 wherein the immunogenic fragment is coupled to a carrier.
7. An isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide that has at least 85% identity to the amino acid sequence of SEQ ID NO:2, 4 over the entire length of SEQ ID NO:2, 4 respectively; or a nucleotide sequence complementary to said isolated polynucleotide.

8. An isolated polynucleotide comprising a nucleotide sequence that has at least 85% identity to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2, 4 over the entire coding region; or a nucleotide sequence complementary to said isolated polynucleotide.

9. An isolated polynucleotide which comprises a nucleotide sequence which has at least 85% identity to that of SEQ ID NO:1, 3 over the entire length of SEQ ID NO:1, 3 respectively; or a nucleotide sequence complementary to said isolated polynucleotide.

10. The isolated polynucleotide as claimed in any one of claims 7 to 9 in which the identity is at least 95% to SEQ ID NO:1, 3.

11. An isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:2, SEQ ID NO:4.

12. An isolated polynucleotide comprising the polynucleotide of SEQ ID NO:1, SEQ ID NO:3.

13. An isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:2, SEQ ID NO:4 obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1, SEQ ID NO:3 or a fragment thereof.

14. An expression vector or an isolated live microorganism comprising a recombinant polynucleotide according to any one of claims 7 to 13.

15. A host cell comprising the expression vector of claim 14 or a subcellular fraction or a membrane of said host cell expressing an isolated polypeptide comprising an amino acid sequence that has at least 85% identity to the amino

acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4.

16. A process for producing a polypeptide comprising an amino acid sequence that has at least 85% identity to the amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:4 comprising culturing a host cell of claim 15 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium.

17. A process for expressing a polynucleotide of any one of claims 7 to 14 comprising transforming a host cell with the expression vector comprising at least one of said polynucleotides and culturing said host cell under conditions sufficient for expression of any one of said polynucleotides.

18. A vaccine composition comprising an effective amount of the polypeptide of any one of claims 1 to 6 and a pharmaceutically acceptable carrier.

19. A vaccine composition comprising an effective amount of the polynucleotide of any one of claims 7 to 13 and a pharmaceutically effective carrier.

20. The vaccine composition according to either one of claims 18 or 19 wherein said composition comprises at least one other *Neisseria meningitidis* antigen.

21. An antibody immunospecific for the polypeptide or immunological fragment as claimed in any one of claims 1 to 6.

22. A method of diagnosing a *Neisseria meningitidis* infection, comprising identifying a polypeptide as claimed in any one of claims 1 to 6, or an antibody

that is immunospecific for said polypeptide, present within a biological sample from an animal suspected of having such an infection.

23. Use of a composition comprising an immunologically effective amount of a polypeptide as claimed in any one of claims 1 to 6 in the preparation of a medicament for use in generating an immune response in an animal.

24. Use of a composition comprising an immunologically effective amount of a polynucleotide as claimed in any one of claims 7 to 13 in the preparation of a medicament for use in generating an immune response in an animal.

25. A therapeutic composition useful in treating humans with *Neisseria meningitidis* disease comprising at least one antibody directed against the polypeptide of claims 1 to 6 and a suitable pharmaceutical carrier.

1/12

**Fig.1**

Alignment of the BASB029 polynucleotide sequences.

Identity to SeqID No:1 is indicated by a dot, and a dash ("") indicates a missing nucleotide.

\*                  20                  \*                  40                  \*

Seqid1:ATGAACAAAATATACCGCATCATTGGAATAGTGCCCTCAATGCCTGGGT:50  
 Seqid3:.....:50

60                  \*                  80                  \*                  100

Seqid1:CGCCGTATCCGAGCTCACACGCAACCACACCAACGCGCCTCCGCAACCG:100  
 Seqid3:.....:100

\*                  120                  \*                  140                  \*

Seqid1:TGGCGACCGCCGTATTGGCGACACTGTTGTTGCAACGGTCAGGCGAGT:150  
 Seqid3:..AA.....A...:150

160                  \*                  180                  \*                  200

Seqid1:ACTACCGAT-----GACGACGATTATTTAGAACCCGTACAACG:191  
 Seqid3:G...A.A..GAAGAGCAA..A..A.....C.....:200

\*                  220                  \*                  240                  \*

Seqid1:CACTGCTGTCGTGTTGAGCTTCCGTTCCGATAAAGAAGGGACGGGAGAAA:241  
 Seqid3:....T..C.....TAG..AA.....:250

260                  \*                  280                  \*                  300

Seqid1:AAG---AAGTTACAGAAGATTCAAATTGGGGAGTATATTCGACAAGAAA:288  
 Seqid3:.. AAA....AGA....A....G....C.....A..G....:300

\*                  320                  \*                  340                  \*

Seqid1:GGAGTACTAACAGCCGGAACAAATCACCTCAAAGCCGGCGACAACCTGAA:338  
 Seqid3:.....A..GA.....:350

2/12

360 \* 380 \* 400

Seqid1:AATCAAACAAACACCAATGAAAACACCAATGCCAGTAGCTTACCTACT:388  
Seqid3:.....-----G..CA.A.....:382

\* 420 \* 440 \*

Seqid1:CGCTGAAAAAAGACCTCACAGATCTGACCAGTGTGGAACTGAAAAATT:438  
Seqid3:.....:432

460 \* 480 \* 500

Seqid1:TCGTTAGCGAAACAGCAATAAAGTCAACATCACAGCGACACCAAAGG:488  
Seqid3:.....G.....:482

\* 520 \* 540 \*

Seqid1:CTTGAATTCGCAGAAAAAACGGCTGAGACCAACGGCGACACCGGTT:538  
Seqid3:.....T.....G.....G.....:532

560 \* 580 \* 600

Seqid1:ATCTGAACGGTATCGGTTGACTTGACCGATACTGCTGTAATACCGGA:588  
Seqid3:..C.....T.....:582

\* 620 \* 640 \*

Seqid1:GCGACCACAAACGTAACCAACGACAACGTTACCGATGACGAGAAAAACG:638  
Seqid3:.....:632

660 \* 680 \*

Seqid11:TGGGGCAAGCGTTAAAGACGTATTAAACGCAAGCTGGAACATTAAAGGCG:688  
Seqid3: ..:682

3/12

\* 720 \* 740 \*

Seqid1: TTAAACCCGGTACAACAGCTTCGATAACGTTGATTCGTCCGACTTAC:738

Seqid3: .....:732

760 \* 780 \* 800

Seqid1: GACACAGTCGAGTTCTTGAGCGCAGATAACGAAAACAACGACTGTTAATGT:788

Seqid3: .....:782

\* 820 \* 840 \*

Seqid1: GGAAAGCAAAGACAACGGCAAGAGAACCGAAGTTAAATCGGTGCGAAGA:838

Seqid3: .....A.....:832

860 \* 880 \* 900

Seqid1: CTTCTGTTATCAAAGAAAAAGACGGTAAGTTGGTTACTGGTAAAGACAAA:888

Seqid3: .....T.....:882

\* 920 \* 940 \*

Seqid1: GGCGAGAATGATTCTTCTACAGACAAAGGCGAAGGCCTAGTGACTGCAA:938

Seqid3: .....G.....G.....:932

960 \* 980 \* 1000

Seqid1: AGAAGTGATTGATGCAGTAAACAAGGCTGGTGGAGAATGAAAACAACAA:988

Seqid3: .....:982

\* 1020 \* 1040 \*

Seqid1: CCGCTAATGGTCAAACAGGTCAAGCTGACAAGTTGAAACCGTTACATCA:1038

Seqid3: .....:1032

1060 \* 1080 \* 1100

Seqid1: GGCACAAATGTAACCTTGCTAGTGGTAAAGGTACAACGTGCGACTGTAAG:1088

Seqid3: .....:1082

**4/12**

\* 1120 \* 1140 \*

Seqid1:TAAAGATGATCAAGGCAACATCACTGTTATGTATGTAATGTCGGCG:1138  
Seqid3:.....:1132

1160 \* 1180 \* 1200

Seqid1:ATGCCCTAACGTCAATCAGCTGAAAACAGCCGTTGGAATTGGATTCC:1188  
Seqid3:.....:1182

\* 1220 \* 1240 \*

Seqid1:AAAGCGGTTGCAGGTTCTCGGGCAAAGTCATCAGCGGCAATGTTGCC:1238  
Seqid3:.....:1232

1260 \* 1280 \* 1300

Seqid1:GAGCAAGGGAAAGATGGATGAAACCGTCAACATTAATGCCGGACAACA:1288  
Seqid3:.....:1282

\* 1320 \* 1340 \*

Seqid1:TCGAGATTACCCGCAACGGAAAAATATGACATGCCACTCGATGACC:1338  
Seqid3:.....T.....:1332

1360 \* 1380 \* 1400

Seqid1:CCGCAATTTCCAGCGTTCGCTGGCGGGGGCGGATGCGCCCACTT:1388  
Seqid3:....G.....:1382

\* 1420 \* 1440 \*

Seqid1:AAGCGTGGATGACGAGGGCGCGTTGAATGTCGGCAGCAAGGATGCCAACA:1438  
Seqid3:G.....G..A...A.....A.G.A....:1429

5/12

1460 \* 1480 \* 1500

Seqid1: AACCCGTCCGCATTACCAATGTCGCCCGGGCGTTAAAGAGGGGGATGTT:1488  
Seqid3: .....:1479

\* 1520 \* 1540 \*

Seqid1: ACAAACGTCGACAACCTAAAGGCGTGGCGAAAACCTGAACAACCACAT:1538  
Seqid3: .....G...:1529

1560 \* 1580 \* 1600

Seqid1: CGACAATGTGGACGGCAACGCGCGTGCAGGCATGCCAAGCGATTGCAA:1588  
Seqid3: .....:1579

\* 1620 \* 1640 \*

Seqid1: CCGCAGGTCTGGTTAGGCGTATCTGCCCGGCAAGAGTATGATGGCGATC:1638  
Seqid3: .....T.....:1629

1660 \* 1680 \* 1700

Seqid1: GGCGGCGGCACTTATCGCGGCGAAGCCGGTTATGCCATCGGCTACTCAAG:1688  
Seqid3: .....C.....C.:1679

\* 1720 \* 1740 \*

Seqid1: CATTCCGACGGCGGAAATTGGATTATCAAAGGCACGGCTTCCGGCAATT:1738  
Seqid3: T.....:1729

1760 \* 1780 \*

Seqid1: CGCGCGGCCATTCGGTCTCCGCATCTGTCGGTTATCAGTGGTAA:1785  
Seqid3: .....:1776

6/12

**Fig.2**

Alignment of the BASB029 polypeptide sequences.

Identity to SeqID No:2 is indicated by a dot, and a dash ("") indicates a missing amino acid.

\* 20 \* 40 \*

Seqid2: MNKIYRIIWN SALNAW VAV SELTRN HTKR ASATVATA VLAT LLFATV QAS: 50  
 Seqid4: ..... K.....: 50

60 \* 80 \* 100

Seqid2: T---TDDDDLYLEPVQRTAVVLSFRSDKEGTGEKE-VTEDSNWGVYFDKK: 96  
 Seqid4: ANNEEQEE ....D....VA..IVN.....K.E....A....E.: 100

\* 120 \* 140 \*

Seqid2: GVLTAGTITLKAGDN LKIKQNTNENTNASSFTYSLKKDLT DLT SGTEKL: 146  
 Seqid4: .....RE.....----G N.....: 144

160 \* 180 \* 200

Seqid2: SFSANSNKVNITSDTKGLNFAKKTAETNGDTTVHLNGIGSTLTDLLNTG: 196  
 Seqid4: .....G.....E..G.....: 194

\* 220 \* 240 \*

Seqid2: ATTNVTNDNVTDDEKKRAASVKDVLNAGWN IKGVKPGTTASDNVDFVRTY: 246  
 Seqid4: .....: 244

260 \* 280 \* 300

Seqid2: DTVEFLSADTKTTTVNVESKDNGKRTEVKIGAKTSVIKEKGKLV TGKDK: 296  
 Seqid4: .....: 294

\* 320 \* 340 \*

Seqid2: GENDSSTDKGEGLVTAKEVIDAVN KAGWRMKT TANGQTGQADKFETVTS: 346  
 Seqid4: ...G....E.....: 344

7/12

360 \* 380 \* 400

Seqid2: GTNVTFASGKTTATVKDDQGNITVMDVNVDALNVNQLQNSGWNLDS:396  
Seqid4: .....:394

\* 420 \* 440 \*

Seqid2: KAVAGSSGKVISGNVSPSKGKMDETVNINAGNNIEIRNGKNIDIATSMT:446  
Seqid4: .....:444

460 \* 480 \* 500

Seqid2: PQFSSVSLGAGADAPTLSVDEGALNVGSKDANKPVIRTNVAPGVKEGDV:496  
Seqid4: .....GD.....KD.....:493

\* 520 \* 540 \*

Seqid2: TNVAQLKGVAQNLNHHIDNVDGNARAGIAQAIATAGLVQAYLPGKSMMAI:546  
Seqid4: .....R.....:543


560 \* 580 \*

Seqid2: GGGTYRGEAGYAIGYSSISDGGNWIIGTASGNSRGHFGASASVGYQW:594  
Seqid4: .....:591

8/12

**Fig.3** Expression and purification of recombinant BASB029 in E. coli.


A substantially purified BASB029 protein fraction (more than 80%) was separated on a 4-20% gradient polyacrylamide gel (NOVEX) under PAGE-SDS conditions in parallel to a protein molecular weight marker. Gels were either stained with Coomassie Blue R250 (lane 1) or analyzed by western blot using an anti-(His5) monoclonal antibody (lane 2).



9/12

**Fig.4**


Recognition of the BASB029 protein on several NmB strains with BASB029 immunized mice sera



10/12

## Fig.5


Recognition of the BASB029 protein on several NmB strains with  
BASB029 immunized mice sera



11/12

**Fig.6**


Anti-BASB029 antibodies in convalescent sera (part B) and in immunized mice (part A).



12/12

**Fig.7**

Anti-BASB029 antibodies in convalescent sera (part B) and in immunized mice (part A).



**DECLARATION AND POWER OF ATTORNEY**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**BASB029 Polynucleotide(s) and polypeptides from Neisseria Meningitidis**

the specification of which (check one)

[ ] is attached hereto.  
[X] was filed on 7 May 1999 as Serial No. PCT/EP99/03255  
and was amended on \_\_\_\_\_  
(if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

**Prior Foreign Application(s)**

Number	Country	Filing Date	Priority Claimed
9810276.7	Great Britain	13 May 1998	Yes

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number      Filing Date

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal

Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 25,308

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-00  
Full Name of Inventor: Jean-Louis RUELLE

Inventor's Signature: 

Date: Nov. 6<sup>th</sup>, 2000

Residence: Limal, Belgium BEX

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

09/700293

529 Rec'd PCT/PTC 13 NOV 2000

## SEQUENCE LISTING

<110> SmithKline Beecham Biologicals  
Ruelle, Jean-Louis

<120> BASB029 Polynucleotides and Polypeptides  
from Neisseria Meningitidis

<130> BM45321

<150> PCT/EP99/03255  
<151> 1999-05-07

<150> GB 9810276.7  
<151> 1998-05-13

<160> 6

<170> FastSEQ for Windows Version 4.0

<210> 1  
<211> 1785  
<212> DNA  
<213> Bacteria

<400> 1		
atgaacaaaa tataccgcat catttggaaat agtgcctca atgcctgggt cgccgtatcc		60
gagtcacac gcaaccacac caaacgcgcc tccgcaaccg tggcgaccgc cgtattggcg		120
acactgttgt ttgcaacggt tcagggcgagt actaccatg acgacgattt atatttagaa		180
cccgtaaac gcactgtgt cgtgttgagc ttccgttccg ataaaagaagg cacgggagaa		240
aaagaaggta cagaagattc aaattgggaa gtatatttcg acaagaaagg agtactaaca		300
gccggaaaca tcaccctcaa agccggcgac aacctgaaaaa tcaaacaaccaatgaa		360
aacaccaatg ccagtagctt cactactcg ctgaaaaaag acctcacaga tctgaccagt		420
gttggactg aaaaattatc gtttagcgca aacagcaata aagtcaacat cacaagcgac		480
accaaggct tgaatttcgc gaaaaaaaaacg gctgagacca acggcgacac cacggttcat		540
ctgaacggta tcggttcgac tttgaccgtatcgactgctgaaatccggaccacaaac		600
gtaaccaacg acaacgttac cgatgacgag aaaaaacgtg cgccaagcgt taaagacgta		660
ttaaacgcag gctggAACAT taaaggcggtt aaacccgtt caacagcttc cgataacgtt		720
gatttcgtcc gcacttacga cacagtcgag ttcttgagcg cagatacgaa aacaacgact		780
gttaatgtgg aaagcaaaga caacggcaag agaaccgaag ttaaaatcgg tgcaagact		840
tctgttatca aagaaaaaga cggtaagttt gttactggta aagacaaagg cgagaatgat		900
tcttctacag acaaaggcga aggcttagt actgaaaaaag aagtatttgc tgcaatggaa		960
aaggctgggt ggagaatgaa aacaacaacc gctaattgtc aaacaggctca agctgacaag		1020
tttggaaaccg ttacatcagg cacaatgtt acctttgttca gtggtaaagg tacaactcg		1080
actgttaatgtt aagatgtca aggcaacatc actgttatgtt atgatgtaaa tgccggcgat		1140
gccctaaacg tcaatcgat gcaaaacagc gtttggaaatt tgattccaa agccggatgc		1200
ggttttcggtt gcaaaagtcat cagcgccat gtttccggc gcaaggaaa gatggatgaa		1260
accgtcaaca ttaatgccgg caacaacatc gagattaccc gcaacggcaa aaatatcgac		1320
atcgccactt cgatgacccc gcaattttcc agcggttcgc tcggcgccgg ggcggatgc		1380
cccactttaa gcgtggatga cgagggcgcg ttgaatgtcg gcagcaaggta tgccaaacaaa		1440
cccgccgca ttaccaatgtt cggccggccg gttaaaggagg gggatgttac aaacgtcgca		1500
caacttaaag gcgtggcgca aaacttgaac aaccacatcg acaatgtggc cggcaacgc		1560
cgtgcggcga tcgccccaaagc gattgcaacc gcagggtctgg ttccaggcgta tctgccccgc		1620
aagagtatgatgatcg cggccggact tatcgccggc aagccggatgaa tgccatcg		1680
tactcaagca ttcccgacgg cggaaattgg attatcaaag gcaacggcttc cggcaattcg		1740
cgccggcatt tcggtgcttc cgcacatcgatc gtttatcgtt gttaa		1785

<210> 2  
<211> 594  
<212> PRT

&lt;213&gt; Bacteria

<400> 2  
 Met Asn Lys Ile Tyr Arg Ile Ile Trp Asn Ser Ala Leu Asn Ala Trp  
 1 5 10 15  
 Val Ala Val Ser Glu Leu Thr Arg Asn His Thr Lys Arg Ala Ser Ala  
 20 25 30  
 Thr Val Ala Thr Ala Val Leu Ala Thr Leu Leu Phe Ala Thr Val Gln  
 35 40 45  
 Ala Ser Thr Thr Asp Asp Asp Asp Leu Tyr Leu Glu Pro Val Gln Arg  
 50 55 60  
 Thr Ala Val Val Leu Ser Phe Arg Ser Asp Lys Glu Gly Thr Gly Glu  
 65 70 75 80  
 Lys Glu Val Thr Glu Asp Ser Asn Trp Gly Val Tyr Phe Asp Lys Lys  
 85 90 95  
 Gly Val Leu Thr Ala Gly Thr Ile Thr Leu Lys Ala Gly Asp Asn Leu  
 100 105 110  
 Lys Ile Lys Gln Asn Thr Asn Glu Asn Thr Asn Ala Ser Ser Phe Thr  
 115 120 125  
 Tyr Ser Leu Lys Lys Asp Leu Thr Asp Leu Thr Ser Val Gly Thr Glu  
 130 135 140  
 Lys Leu Ser Phe Ser Ala Asn Ser Asn Lys Val Asn Ile Thr Ser Asp  
 145 150 155 160  
 Thr Lys Gly Leu Asn Phe Ala Lys Lys Thr Ala Glu Thr Asn Gly Asp  
 165 170 175  
 Thr Thr Val His Leu Asn Gly Ile Gly Ser Thr Leu Thr Asp Thr Leu  
 180 185 190  
 Leu Asn Thr Gly Ala Thr Thr Asn Val Thr Asn Asp Asn Val Thr Asp  
 195 200 205  
 Asp Glu Lys Lys Arg Ala Ala Ser Val Lys Asp Val Leu Asn Ala Gly  
 210 215 220  
 Trp Asn Ile Lys Gly Val Lys Pro Gly Thr Thr Ala Ser Asp Asn Val  
 225 230 235 240  
 Asp Phe Val Arg Thr Tyr Asp Thr Val Glu Phe Leu Ser Ala Asp Thr  
 245 250 255  
 Lys Thr Thr Val Asn Val Glu Ser Lys Asp Asn Gly Lys Arg Thr  
 260 265 270  
 Glu Val Lys Ile Gly Ala Lys Thr Ser Val Ile Lys Glu Lys Asp Gly  
 275 280 285  
 Lys Leu Val Thr Gly Lys Asp Lys Gly Glu Asn Asp Ser Ser Thr Asp  
 290 295 300  
 Lys Gly Glu Gly Leu Val Thr Ala Lys Glu Val Ile Asp Ala Val Asn  
 305 310 315 320  
 Lys Ala Gly Trp Arg Met Lys Thr Thr Ala Asn Gly Gln Thr Gly  
 325 330 335  
 Gln Ala Asp Lys Phe Glu Thr Val Thr Ser Gly Thr Asn Val Thr Phe  
 340 345 350  
 Ala Ser Gly Lys Gly Thr Thr Ala Thr Val Ser Lys Asp Asp Gln Gly  
 355 360 365  
 Asn Ile Thr Val Met Tyr Asp Val Asn Val Gly Asp Ala Leu Asn Val  
 370 375 380  
 Asn Gln Leu Gln Asn Ser Gly Trp Asn Leu Asp Ser Lys Ala Val Ala  
 385 390 395 400  
 Gly Ser Ser Gly Lys Val Ile Ser Gly Asn Val Ser Pro Ser Lys Gly  
 405 410 415  
 Lys Met Asp Glu Thr Val Asn Ile Asn Ala Gly Asn Asn Ile Glu Ile  
 420 425 430  
 Thr Arg Asn Gly Lys Asn Ile Asp Ile Ala Thr Ser Met Thr Pro Gln  
 435 440 445  
 Phe Ser Ser Val Ser Leu Gly Ala Gly Ala Asp Ala Pro Thr Leu Ser  
 450 455 460  
 Val Asp Asp Glu Gly Ala Leu Asn Val Gly Ser Lys Asp Ala Asn Lys

465	470	475	480
Pro Val Arg Ile Thr Asn Val Ala Pro Gly Val Lys Glu Gly Asp Val			
485	490	495	
Thr Asn Val Ala Gln Leu Lys Gly Val Ala Gln Asn Leu Asn Asn His			
500	505	510	
Ile Asp Asn Val Asp Gly Asn Ala Arg Ala Gly Ile Ala Gln Ala Ile			
515	520	525	
Ala Thr Ala Gly Leu Val Gln Ala Tyr Leu Pro Gly Lys Ser Met Met			
530	535	540	
Ala Ile Gly Gly Gly Thr Tyr Arg Gly Glu Ala Gly Tyr Ala Ile Gly			
545	550	555	560
Tyr Ser Ser Ile Ser Asp Gly Gly Asn Trp Ile Ile Lys Gly Thr Ala			
565	570	575	
Ser Gly Asn Ser Arg Gly His Phe Gly Ala Ser Ala Ser Val Gly Tyr			
580	585	590	
Gln Trp			

<210> 3  
<211> 1776  
<212> DNA  
<213> Bacteria

<400> 3	
atgaacaaaa tataccgcat catttggaat agtgcctca atgcctgggt cgccgttatcc	60
gagctcacac gcaaccacac caaacgcgcc tccgcAACCG tgaagaccgc cgtattggcg	120
acactgttgt ttgcaacggc tcaggcaagt gctaacaatg aagagcaaga agaagattta	180
tatttagacc ccgtacaacg cactgttgcc gtgttgatag tcaattccga taaagaaggc	240
acgggagaaa aagaaaaagt agaagaaaat tcagatggg cagtatattt caacgagaaa	300
ggagttactaa cagccagaga aatcaccctc aaagccggcg acaacctgaa aatcaaaca	360
aacggcacaa acttcaccta ctcgctgaaa aaagacctca cagatctgac cagtgttgaa	420
actgaaaaat ttcgttttag cgcaaaacggc aataaaatc acatcacaag cgacacacaa	480
ggcttgaatt ttgcgaaaga aacggctggg acgaacggcg acaccacggt tcacctgaa	540
gttattgggt cgactttgac cgatacgtg ctgaataccg gagcggaccac aaacgtaacc	600
aacgacaacg ttaccgatga cgagaaaaaa cgtgcggcaa gcgttaaaga cgtattaaac	660
gcaggctgga acattaaagg cgttaaaccg ggtacaacag cttccgataa cgttggattc	720
gtccgcactt acgacacagt cgagttcttg agcgcagata cggaaacaac gactgttaat	780
gtgaaagca aagacaacgg caagaaaaacc gaagttaaaa tcggtgcgaa gacttctgtt	840
attaaagaaa aagacggtaa gttggttact ggttaaagaca aaggcgagaa tggttcttct	900
acagacgaag gcgaaggctt agtgcactgca aaagaagtga ttgatgcagt aaacaaggct	960
ggttggagaa tgaaaacaac aaccgctaatt ggtcaaacag gtcaagctga caagtttga	1020
accgttacat caggcacaaa tgaaccctt gctagttgtt aaggtacaac tgcgactgt	1080
agtaaagatg atcaaggcaa catcaactgtt atgtatgtcg cgatccccta	1140
aacgtcaatc agctgcaaaa cagcggttgg aatttggatt ccaaaggcggt tgcagggtct	1200
tcgggcaag tcatcagcgg caatgtttcg ccgagcaagg gaaagatgga taaaaccgtc	1260
aacattaatg ccggcaacaa catcgagatt acccgcaacg gtaaaaatat cgacatcgcc	1320
acttcgatga cccccgcaattt ttcacgcgtt tcgctcgcc cgaaaaaccc tgcgcccact	1380
ttgagcgtgg atggggacgc attgaatgtc ggcagcaaga aggacaacaa acccgccgc	1440
attaccaatg tcgccccggg cgttaaagag ggggatgtt caaacgtcgc acaacttaaa	1500
ggcgtggcgc aaaacttcaa caaccgcattt gacaatgtgg acggcaacgc gctgtggcgc	1560
atcgcccaag cgattgcaac cgcaggcttg gttcaggcgt atttgcggg caagagtatg	1620
atggcgtatcg gcggcggcac ttatcgcggc gaagccgggtt acgcccattgg ctactccagt	1680
atttccgacg gcgaaattt gattatcaa ggcacggtt ccggcaattt gcgccggcat	1740
ttcggtgtt ccgcacatctgt cggttatcgt tggtaa	1776

<210> 4  
<211> 591  
<212> PRT  
<213> Bacteria

<400> 4  
Met Asn Lys Ile Tyr Arg Ile Ile Trp Asn Ser Ala Leu Asn Ala Trp

1	5	10	15												
Val	Ala	Val	Ser	Glu	Leu	Thr	Arg	Asn	His	Thr	Lys	Arg	Ala	Ser	Ala
		20				25									30
Thr	Val	Lys	Thr	Ala	Val	Leu	Ala	Thr	Leu	Leu	Phe	Ala	Thr	Val	Gln
		35				40									45
Ala	Ser	Ala	Asn	Asn	Glu	Glu	Gln	Glu	Glu	Asp	Leu	Tyr	Leu	Asp	Pro
		50			55										60
Val	Gln	Arg	Thr	Val	Ala	Val	Leu	Ile	Val	Asn	Ser	Asp	Lys	Glu	Gly
		65			70					75					80
Thr	Gly	Glu	Lys	Glu	Lys	Val	Glu	Glu	Asn	Ser	Asp	Trp	Ala	Val	Tyr
		85			90										95
Phe	Asn	Glu	Lys	Gly	Val	Leu	Thr	Ala	Arg	Glu	Ile	Thr	Leu	Lys	Ala
		100			105										110
Gly	Asp	Asn	Leu	Lys	Ile	Lys	Gln	Gly	Thr	Asn	Phe	Thr	Tyr	Ser	
		115			120										125
Leu	Lys	Lys	Asp	Leu	Thr	Asp	Leu	Thr	Ser	Val	Gly	Thr	Glu	Lys	Leu
		130			135										140
Ser	Phe	Ser	Ala	Asn	Gly	Asn	Lys	Val	Asn	Ile	Thr	Ser	Asp	Thr	Lys
		145			150										160
Gly	Leu	Asn	Phe	Ala	Lys	Glu	Thr	Ala	Gly	Thr	Asn	Gly	Asp	Thr	Thr
		165			170										175
Val	His	Leu	Asn	Gly	Ile	Gly	Ser	Thr	Leu	Thr	Asp	Thr	Leu	Leu	Asn
		180			185										190
Thr	Gly	Ala	Thr	Thr	Asn	Val	Thr	Asn	Asp	Asn	Val	Thr	Asp	Asp	Glu
		195			200										205
Lys	Lys	Arg	Ala	Ala	Ser	Val	Lys	Asp	Val	Leu	Asn	Ala	Gly	Trp	Asn
		210			215										220
Ile	Lys	Gly	Val	Lys	Pro	Gly	Thr	Thr	Ala	Ser	Asp	Asn	Val	Asp	Phe
		225			230										240
Val	Arg	Thr	Tyr	Asp	Thr	Val	Glu	Phe	Leu	Ser	Ala	Asp	Thr	Lys	Thr
		245			250										255
Thr	Thr	Val	Asn	Val	Glu	Ser	Lys	Asp	Asn	Gly	Lys	Lys	Thr	Glu	Val
		260			265										270
Lys	Ile	Gly	Ala	Lys	Thr	Ser	Val	Ile	Lys	Glu	Lys	Asp	Gly	Lys	Leu
		275			280										285
Val	Thr	Gly	Lys	Asp	Lys	Gly	Glu	Asn	Gly	Ser	Ser	Thr	Asp	Glu	Gly
		290			295										300
Glu	Gly	Leu	Val	Thr	Ala	Lys	Glu	Val	Ile	Asp	Ala	Val	Asn	Lys	Ala
		305			310										320
Gly	Trp	Arg	Met	Lys	Thr	Thr	Ala	Asn	Gly	Gln	Thr	Gly	Gln	Ala	
		325			330										335
Asp	Lys	Phe	Glu	Thr	Val	Thr	Ser	Gly	Thr	Asn	Val	Thr	Phe	Ala	Ser
		340			345										350
Gly	Lys	Gly	Thr	Thr	Ala	Thr	Val	Ser	Lys	Asp	Asp	Gln	Gly	Asn	Ile
		355			360										365
Thr	Val	Met	Tyr	Asp	Val	Asn	Val	Gly	Asp	Ala	Leu	Asn	Val	Gln	
		370			375										380
Leu	Gln	Asn	Ser	Gly	Trp	Asn	Leu	Asp	Ser	Lys	Ala	Val	Ala	Gly	Ser
		385			390										400
Ser	Gly	Lys	Val	Ile	Ser	Gly	Asn	Val	Ser	Pro	Ser	Lys	Gly	Lys	Met
		405			410										415
Asp	Glu	Thr	Val	Asn	Ile	Asn	Ala	Gly	Asn	Asn	Ile	Glu	Ile	Thr	Arg
		420			425										430
Asn	Gly	Lys	Asn	Ile	Asp	Ile	Ala	Thr	Ser	Met	Thr	Pro	Gln	Phe	Ser
		435			440										445
Ser	Val	Ser	Leu	Gly	Ala	Gly	Ala	Asp	Ala	Pro	Thr	Leu	Ser	Val	Asp
		450			455										460
Gly	Asp	Ala	Leu	Asn	Val	Gly	Ser	Lys	Asp	Asn	Lys	Pro	Val	Arg	
		465			470										480
Ile	Thr	Asn	Val	Ala	Pro	Gly	Val	Lys	Glu	Gly	Asp	Val	Thr	Asn	Val
		485			490										495
Ala	Gln	Leu	Lys	Gly	Val	Ala	Gln	Asn	Leu	Asn	Asn	Arg	Ile	Asp	Asn

500 505 510  
Val Asp Gly Asn Ala Arg Ala Gly Ile Ala Gln Ala Ile Ala Thr Ala  
515 520 525  
Gly Leu Val Gln Ala Tyr Leu Pro Gly Lys Ser Met Met Ala Ile Gly  
530 535 540  
Gly Gly Thr Tyr Arg Gly Glu Ala Gly Tyr Ala Ile Gly Tyr Ser Ser  
545 550 555 560  
Ile Ser Asp Gly Gly Asn Trp Ile Ile Lys Gly Thr Ala Ser Gly Asn  
565 570 575  
Ser Arg Gly His Phe Gly Ala Ser Ala Ser Val Gly Tyr Gln Trp  
580 585 590

<210> 5  
<211> 36  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide

<400> 5  
ggggcatatg aacaaaatat accgcattcat ttggaa

36

<210> 6  
<211> 34  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide

<400> 6  
ggggctcgag ccactgataa ccgacagatg cgga

34